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Abstract
For oral drug formulations, the efficacy of a formulation in an individual is dependent
on many physiological processes and variables. For most immediate release drug
products, the formulation must disintegrate and dissolve, undissolved mass must empty
from the stomach into the upper gastrointestinal (GI) tract, and remaining undissolved
drug must dissolve and be absorbed across the intestinal wall to reach systemic
circulation. Despite understanding the relevant processes, conventional in vitro
methods only capture a part of these processes by performing dissolution at one pH
without any other processes acting on the formulation. In this work, a dissolution
device is developed that simulates the relevant in vivo processes that can affect drug
dissolution. This device is called the Gastro-Intestinal Simulator or (GIS) and is
designed to simulate in vivo conditions in a way that maintains ease of use. Compared
to other multi-vessel dissolution devices, the GIS can be run multiple times in a day by
just one analyst. The device has been designed with customizability in mind, with the
ability for vessel geometry to be easily selected, a variety of gastric emptying rates
applied, and a titration function to maintain pH in the chamber representing the upper
intestine (e.g. duodenum) when using biorelevant media. Applications of the device
were evaluated with two sets of experiments: determination of in vitro – in vivo
correlations (IVIVC), and formulation screening tests to determine sensitivity to
formulation variables and results compared to conventional testing procedures. IVIVCs
are a valuable tool in quantifying drug release into systemic circulation but require
physiologically relevant dissolution data. The dissolution data generated for two
ibuprofen formulations in the GIS did not produce a successful IVIVC. Although the
results of this work failed to meet strict FDA requirements for an IVIVC, the results
showed promise and provide a framework for future correlative dissolution. The GIS
xv
system has the capability for further optimization to better represent the conditions of
the human intestine, which could allow for improved correlations including biorelevant
media selection, gastric emptying, and introduction of an absorption compartment. For
formulation optimization, a similar framework as other industrial process optimizations
can be applied. However, multiple process and formulation variables increases the
challenge of developing an understanding of these effects and therefore benefits from
an appropriate experimental design. This empirical approach requires a statistical
design of experiments and a Plackett-Burman design was selected as a screening
approach designed to limit the number of experiments to determine the main effects of
interest. The GIS results showed the most statistically significant factors compared to
compendial disintegration and dissolution methods. In both applications, the GIS, when
configured to simulate the relevant conditions of the human intestine showed
significant promise for assessing formulations and mechanisms that lead to improved in
vivo drug dissolution.
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Chapter 1.
Introduction
The reduction of drug costs must occur without removing necessary regulatory controls
to prevent patient harm. This does not prevent novel technologies from being created to
reduce expensive testing for drug products that may eventually fail during pre-clinical
or clinical testing. Attrition levels have been consistently high, ranging from 10-21% of
all drug products that enter Phase I clinical human testing will reach the market 1. With
pharmaceutical research and development (R&D) costs projected to grow to almost $160
billion USD by 2020 2 and the desire to outpace patent expiration, there is little luxury
for industrial scientists to research processes fundamental to producing optimal drug
formulations. The idea of studying the fundamental processes of oral formulations is
not one denounced by the pharmaceutical industry. By understanding these processes,
improved predictions can be created to reduce adverse effects on patients, thereby
improving safety, and enhance efficacy of the drug molecule in vivo. In order to provide
added value to R&D, a cost efficient, robust in vitro test or set of tests is necessary to
properly predict differences between formulations for a specific drug product.
A greater understanding of underlying mechanisms have been an ongoing area of
research for the past half century. The biopharmaceutical classification system (BCS)
was created to categorize molecules by two of their key physical chemical properties:
solubility and permeability 3,4. The system provided a binary methodology to guide
product viability and necessary formulation excipients to ensure proper dissolution and
absorption kinetics. The BCS was the basis for the creation of the biowaivers system by
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the FDA 4 to assist generic companies in rapidly generating generic products. Further
iteration of the original BCS has been used to differentiate between molecule species
that have similar physical properties, but differing ionization behaviors, (i.e. weak acid
or weak base). By others, the BCS has been modified into a three-region coordinate
system based on fraction of dose absorbed, with each region delineated by its expected
or measured fraction absorbed. 5 The BCS has been recently expanded to provide
further guidance for in vitro/in vivo correlative (IVIVC) dissolution. This expansion
provides subclassifications within the BCS II class (and BCS class IV, as necessary):
subclass IIa, b & c for weak acids, weak bases, and neutral, or unionizable, drugs,
respectively. 6 In order to provide a robust, simple solution to current need for
consistent IVIVC methodology, there are two necessary arms of research that must be
performed. First, adequately estimating the hydrodynamics of the in vivo
gastrointestinal tract mechanically in vitro is necessary to approximate dissolution
kinetics under certain circumstances. Second, the BCS, and the refinements from the
original system, can be wielded alongside research into biorelevant dissolution media to
provide a systematic means to determine drug formulation viability in the
pre-formulation and formulation stages. In addition, the studies previously performed
on weakly basic drugs in bicarbonate buffer will be expanded upon to improve the
equivalent phosphate buffer relationship.
1.1. Theory of Mass Transfer, Dissolution and the
Gastrointestinal Tract
1.1.1. Solubility and the Boundary Layer Theorm
Molecules must be dissolved into solution in order for transport across the
gastrointestinal membrane, which is almost always needed to cause the desired effect of
the drug. Solubility, or the extent of dissolution, is the maximum concentration of a
drug that can be dissolved into a specific medium. Generally in pharmaceutical
sciences, solubility is the term used for kinetic solubility, or the concentration at which
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a precipitate first appears. This tends to overestimate as compared to the
thermodynamic solubility, but kinetic solubility is a more simple determination can
provide a generally adequate estimation. For most mass transfer situations, Fick’s laws
of diffusion, named after its creator Adolf Fick in 1855, are the typical starting point.
Fick’s first and second laws of diffusion are show below, respectively:
𝐽 = −𝐷𝛿𝐶𝛿𝑥 (1.1)
𝛿𝐶
𝛿𝑡 = −𝐷
𝛿2𝐶
𝛿2𝑥 (1.2)
where J molar flux, in units of moles per area-time, D is the diffusion coefficient in area
per time, C is concentration in moles, and x is the unit of length over which diffusion is
occurring. Fick’s first law, equation 1.1, has been simplified from the typical chemical
engineering form where temperature dependence for density, viscosity and species
specific diffusion coefficients can appear at extreme temperatures, and any presumed
reaction rate is minimal or unrelated to dissolution. Fick’s second law, in equation 1.2,
has also been simplified and is shown in the rectangular coordinate form. This was
simplification can be justified by the assumption that generally there will be little to no
variation in the angular directions of theta and phi, that is the angle between the x-axis
and the y-z-plane and the angle between the z-axis and the x-y plane, respectively.
Fick’s law has some disadvantages as it can cause an oversimplification of the system,
but due to the nature of the differential equations, the boundary conditions can increase
in complexity to match the system. For most oral drug products, dissolution rate is not
solely based on the physicochemical properties of the drug molecule. Disintegration of
particles assists in increasing the rate of in vivo and in vitro dissolution. This occurs
due to the increase in surface area. This increase in dissolution rate related to an
increase in surface area is shown in the Noyes-Whitney equation for dissolution rate
7,9,10, shown below in equation 1.3:
𝛿𝑚
𝛿𝑡 = 𝑘𝑑𝑖𝑠𝑠(𝐶𝑠 − 𝐶0) = 𝐴𝑘𝑚𝑎𝑠𝑠(𝐶𝑠 − 𝐶0) = 𝐴𝑘𝑚𝑎𝑠𝑠Δ𝐶 (1.3)
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where kdiss is the dissolution rate coefficient in volume per time, kmass is the mass
transfer coefficient in distance per time, A is the total surface area of the system, Cs is
the kinetic solubility at the solid surface in mass per volume and C0 is the bulk drug
concentration in mass per volume. By increasing the total number of particles, thereby
increasing the effective surface area, the dissolution rate increases. In order to model
the rate of change of the concentration, the Noyes-Whitney equation can be rearranged
into the form shown below in equation 1.4:
𝛿𝐶0
𝛿𝑡 =
𝐴𝐷
ℎ (𝐶𝑠 − 𝐶0) (1.4)
where D is the effective diffusion coefficient and h is the thickness of the boundary layer
in units of distance. The boundary layer is an important parameter for determining rate
and extent of dissolution. The boundary layer describes a thin layer of unmixed fluid at
the surface of a solid. See Figure 1.1 for a schematic of the boundary layer: The
Figure 1.1: Concentration field gradient with respect to the particle surface with diffusion
into the boundary layer.
boundary layer, thickness δ, is shown in Figure 1.1, for a particle with a radius of R(t),
and a bulk solution concentration of Cb. The figure also shows the expected
concentration gradient with respect to r, the distance from the center of the particle. As
time increases and the particle begins to dissolve, the boundary layer begins to shrink.
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The boundary layer will shrink until the concentration in the boundary is equal to the
maximum solubility. Generally, the boundary layer for highly kinetic fluids, like gases,
is assumed to be smaller than the particle radius. This assumption is not applicable for
aqueous systems like pharmaceutical dissolution and typically a boundary layer on the
same order of magnitude as the particle radius is used. 8, 22 This is likely not perfectly
applicable to regions of the GI like the mucosa, because of the high viscosity of the
mucosa increasing the boundary layer thickness, but diffusion into the mucosa can
likely be encompassed into the absorption component of IVIVC dissolution.
Understanding the boundary layer provides insight into two phenomena surround
stagnant film diffusion from solids: particle confinement and particle size effect. Particle
confinement is a nonideal circumstance for dissolution where there is not sufficient
time, volume or inter-particle spacing for dissolution to occur completely. Though this
circumstance departs for an ideal system, it allows for an understanding of undissolved
drug: as a single particle approaches the drug molecules solubility limit locally, the
dissolution rate will slow, causing saturation to occur without fully dissolving the drug
in the system. It has been observed that duodenal volumes are typically much lower
than the typical dissolution volume (50 mL vs 900 mL), so the particle confinement
effect is a crucial part of modeling the GI. The other phenomenon related to boundary
layer is regarding the effect of particle size on dissolution. Pharmaceutical science
models, like Noyes-Whitney, do not account for particle size as a part of the equation,
though one could argue that a decrease in particle size does increase dissolution rate by
increasing the area to volume ratio. Uniform particle size is highly improbable, but a
rational estimation may be used for boundary layer calculations, with the desire for an
approximately normal distribution and any particles larger or smaller than the used for
boundary layer calculations will approximately cancel each other out. There is some
disagreement on whether the thickness of the boundary layer is constant, has an
effective maximum or has an empirical relationship with particle size that is a strong
approximation over certain ranges. For the sake of simplicity, a constant boundary
layer may be applicable when there is a very small range of particle sizes in the system,
but tends to be not as accurate at estimating boundary layer size across larger ranges.
The Hintz-Johnson model is an empirical model that claims there is a maximum
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boundary layer size once a critical particle size radius is reached. However, Wang et al.,
claim the assigning of a maximum boundary layer is not supported by the laws of
conservation of energy and are merely an empirical adjustment factor to create a better
fit to observed dissolution data 8. One simple means for approximating the boundary
layer thickness is by using the Sherwood number (Sh). The use of the Sherwood
number is commonly used in the engineering field to describe mass transport systems,
but its use in the pharmaceutical sciences realm is relatively recent 10. The Sherwood
number is a dimensionless number, as described in equation 1.5, below:
𝑆ℎ = 𝐾𝐷
𝐿
= 𝑀𝑎𝑠𝑠𝑇 𝑟𝑎𝑛𝑠𝑓 𝑒𝑟𝑅𝑎𝑡𝑒𝐷𝑖𝑓 𝑓 𝑢𝑠𝑖𝑜𝑛𝑅𝑎𝑡𝑒 (1.5)
where K is the mass transfer coefficient and D is the mass diffusivity, in units of area
over time and L is the characteristic length. For the typical drug dissolution system, the
characteristic length is equal to the particle diameter. By comparing the
Noyes-Whitney equation to the mass transfer equation from fluid dynamics, the
following equations can be surmised to determine boundary layer thickness:
𝐴𝐷
ℎ (𝐶𝑠 − 𝐶0) =
𝐴𝐷(𝑆ℎ)
𝐿 (𝐶𝑠 − 𝐶0) (1.6)
1
ℎ =
(𝑆ℎ)
𝐿 (1.7)
Generally, the Sherwood number is applied for a local point on the drug particle as
conditions may cause mass transfer to differ from point to point. To approximate the
average Sherwood number for a drug particle, the Ranz-Marshall equation can be
applied, using the Reynolds number (Re) and the Schmitt number (Sc) 10. The Reynolds
number is a dimensionless number that describes the type of flow that’s occurring,
whether it is turbulent or laminar. The Schmitt number describes the ratio of the
viscous sheer diffusion compared to the mass diffusion rate. The Ranz-Marshall
equation, the Reynolds and Schmitt Numbers equations are shown below in equation
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1.8-1.10:
𝑆ℎ𝑝𝑎𝑟 𝑡𝑖𝑐𝑙𝑒 = 2 + 0.6𝑅𝑒
1
2 𝑆𝑐
1
3 (1.8)
𝑅𝑒 = 𝑈 𝑑𝜈 (1.9)
𝑆𝑐 = 𝜈𝐷 (1.10)
Where υ is the kinematic viscosity of the media, d is the particle diameter, U is the
particle velocity and D is the diffusivity. The first term of the Sherwood number is
present to allow mass transfer that occurs when the system has no flow, or Re = 0; the
second term is the convective diffusion, dominated by the Reynolds and Schmitt
numbers. Inserting a form of equation 1.8 without the dimensionless numbers into a
rearranged form of equation 1.7 allows for the boundary layer thickness to be
determined given a known experiment, as shown below in equation 1.11:
ℎ = 𝑑
0.6𝑈 𝑑𝜈
1
2 𝜈
𝐷
1
3
(1.11)
All values in equation 1.11 can be empirically determined or estimated within an
acceptable range for a given experiment. For pharmaceutical sciences, this equation
does not provide a large advantage over the Noyes-Whitney equation due to most
experiments being performed with similarly sized particles in an aqueous media,
however for the sake of comparison the Ranz-Marshall equation is useful. Though the
USP provides guidance for at least 7 apparatuses for dissolution, the most frequently
used is Apparatus 2: paddle dissolution at 37°C. This system, though simple has some
disadvantages in terms of hydrodynamics. First, in order to provide a homogenous
solution for sampling, the mixing speed (in RPM) must be set high enough to attempt to
prevent stagnate particles from depositing on the bottom of the dissolution vessel. This
high rotational speed causes increased shear effects on particles and other solids,
potentially increase the dissolution rate of the solids. Second, despite the high mixing
speed, two types of particles are present: floating particles, caught in the eddys of the
mixing, and stationary particles, typically occurring early in the experiment when a
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tablet has not completely disintegrated; and each particle type must be accounted for
mathematically. The difficulty with tablets on the bottom of the vessel is their
hydrodynamics require computational fluid dynamics (CFD) calculations in order to
determine the flow pattern and the linear velocities present around the outside of the
tablet.
1.1.2. Computational Fluid Dynamics
According to Lomax, Pulliam and Zinng, the goal of computational fluid dynamics
(CFD) is using modeling of known geometry to gain an understanding of fluid flow in
and around the experimental area 12. This includes the phenomena of “dissipation,
diffusion, convection, shock waves, slip surfaces, boundary layers and turbulence” 12.
Typically, CFD has more applications to aerodynamics than pharmaceutical sciences,
but with regards to the latter, CFD has been used in many dissolution studies to
determine hydrodynamics of many vessels. 11, 13 As in most modeling areas, the
selection of criteria, such as the geometry and flow conditions for CFD is crucial to the
accuracy. In addition, selecting which governing equations, Navier-Stokes versus Euler
equations, for instance, and the boundary conditions for the system; the method of
gridding the volume of flow and the numbering system, such as a finite-volume system,
are also crucial. There are commercial software packages, like Fluent by Ansys Inc., that
are typically used to analyze fluid dynamics. These software packages are capable of
solving coupled non-linear partial differential equations for the necessary parameters:
for dissolution studies, this is typically only momentum, since the system is assumed to
be isothermal with mass transport not considered to determine bulk fluid dynamics.
1.2. Bicarbonate Buffer Systems and buffer selection
1.2.1. Comparisons between in vivo and in vitro buffer systems
When it pertains to in vivo predictive dissolution studies, it remains to be determined
the extent of complexity needed to get desired results. A review by Mudie, et al.
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encompasses various studies on the upper GI to determine concentrations of bile salts,
ions, lipids and enzymes that play a role in dissolution and absorption in vivo, along
with summarizing pH, viscosity, surface tension, osmolality and buffering capacity. 14
The importance of these parameters cannot be understated. Surface tension affects
wetting of the drug product, decreased wetting leads to a decreased disintegration,
thereby decreasing the dissolution rate. Viscosity is highly involved in the boundary
layer, which was previously discussed in great detail. Osmolality is a measure of ionic
concentration, or ionic strength, based upon cellular osmotic pressure and ion content.
One study by Kararli, Kirchkoff and Truelove showed that increasing ionic strength in
vitro caused increased dissolution rate for enteric coated formulations.23 Some
parameters, are easily generated, such as pH, viscosity or buffering capacity, can be
easily generated in a manner that simulates in vivo conditions. For instance, buffering
capacity of the GI, regardless of fed or fasted state, is much lower than that of 50 mM
phosphate buffer. Another deviation from typical in vitro analysis is the stomach pH
under a fasted state, though typically simulated using 0.1 N hydrochloric acid, with a
pH around 1.0, the mean pH of the stomach in a fasted state is 2.9 ± 1.97.14 Not only is
that a large variance from the mean, but it is a much higher pH than that typically used
in vivo.
1.2.2. Bicarbonate Buffer and equivalent phosphate buffer
Typically, simple quality control dissolution studies are performed in 50mM phosphate
buffers at a pH between 6.5 and 7. However, this does not adequately resemble the
buffer behavior in vivo. The buffer system of the gastrointestinal tract is a bicarbonate
buffer system, created by carbonic anhydrase enzymes in the pancreas and excreted
into the small intestine. The role of bicarbonate is the prevent damage to the mucosa of
the intestine from secreted acids from the stomach and surrounding region. The
neutralization of acids by bicarbonate creates carbonic acid as a product. Figure 1.2,
below, shows the general scheme of bicarbonate excretion and uptake into the
duodenum. Figure 1.2 shows that there are three pathways for bicarbonate secretion
into the duodenum: uptake from the blood into the intestinal epithelial cells and
9
Figure 1.2: Schematic of duodenal transporters for the bicarbonate secretion and uptake
system.
subsequent secretion via the cystic fibrosis transmembrane conductance receptor
(CFTR) and anion exchange receptor 4 (AE4), intracellular carbonic anhydrase
converting water and carbon dioxide into bicarbonate which utilize the same secretion
mechanisms, and transcellular diffusion through the mucosa. Fasted human intestinal
fluid has been shown to have limited buffer capacity, near the order of magnitude of 10
mM per unit of pH, with presumably a large degree of the buffering capacity being
supplied by the bicarbonate buffer 14. Compared to common dissolution buffers, like
fasted and fed state simulated intestinal and stomach fluid (FaSSIF and FeSSIF,
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respectively), the buffering capacity of human intestinal fluid is five times lower. This is
one major reason why 50 mM phosphate buffer, though sufficient for quality control
dissolution studies where consistency is more important than correlation to in vivo
conditions, is not an adequate buffer under most circumstances where in vivo
correlation is necessary. However, matching buffering capacities between two buffer
systems is not the sole governing parameter, since buffering capacity controls both bulk
pH and surface pH. Krieg, et al, showed that the physiochemical properties of the drug
molecule also play a role in the buffer selection, specifically in determining the pH at
the surface of the dissolving drug. This difference in buffering reactions are shown
below: where reaction 1 governs the bulk buffer system and the pKa of bicarbonate
(6.04) approximates the reaction kinetics 16. In the boundary layer, the carbonic acid to
water and carbon dioxide reaction is unidirectional, as the reaction rate to generate
carbonic acid is unable to compensate for the reaction of carbonic acid in the boundary
layer and the pKa is 3.55. For the in vitro bicarbonate buffer system typically used in
the Amidon lab, carbon dioxide gas is sparged into an isotonic solution and then
adjusted to the desired pH using sodium hydroxide, typically a pH between 6.5 and 7.0.
For this system, carbon dioxide gas is continuously sparged even after the system has
reached equilibrium. This system therefore has a third reaction, which governs the
buffer system, the dissolution of gas into solution. Since experiments do not commence
until the system has reached an equilibrated dissolved carbon dioxide content and pH,
this equilibrium should not affect bulk buffering capacity and pH over a short time
period, but over time the dissolved gas should drive the reaction in the bulk back
towards the initial equilibrium conditions. For this system, the surface pH should act
similar to the in vivo bicarbonate system. Despite the in vivo relevance, the in vitro
carbon dioxide sparged bicarbonate buffer is complicated and requires extra equipment
compared to a conventional apparatus 2 USP dissolution device. These additional
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components may alter homogeneity of the solution, cause delayed drug dissolution due
to solid particles adhering to the additional surfaces or alternative hydrodynamics
caused by the sparging of carbon dioxide and air. In addition, the preparation of
bicarbonate buffer can be tedious due to the precision required in selecting gas flow rate
to ensure proper buffer strength and pH. For this reason, it’s desirable to attempt to find
an equivalent phosphate buffer to give similar dissolution kinetics. Figure 1.3 shows
equivalent phosphate buffers for 15mM isotonic bicarbonate at pH values of 6.0, 6.5 and
7.0. The predicted equivalent phosphate buffer concentration is plotted on the y-axis in
Figure 1.3: Equivalent phosphate buffers to 15 mM isotonic bicarbonate buffer at pH 6.0,
6.5 and 7.0. Weak acids are on the main axes, weak bases are on the inlay.
units of mM of phosphate, and the x-axis is the drug pKa subtracted by the log of the
intrinsic solubility for weak acids; and for weak bases the x-axis is 14 (or pKw)
subtracted by the drug pKa and the log of the intrinsic drug solubility. For each curve,
the Hintz and Johnson approximation for the boundary layer was used (30 µm). The
relationship between the intrinsic solubility and the pKa, or pKw minus pKa and
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intrinisic solubility are both appear in the equation for the irreversible (Reaction 2 on
page 10) reaction, and are multiplied together. If both parameters are altered in equal
but opposite directions, there is no net change in the equation and the surface pH is
assumed to be the same. In this case the same equivalent phosphate can be used for
both drugs. Figure 1.3 also shows the direct role bulk pH has on the system. The more
acidic a bulk pH, the greater the phosphate concentration that is need, and generally for
weak acids at pH 6.0 the equivalent phosphate buffer will exceed the concentration of
the bicarbonate buffer, and in some extreme cases, even surpass the ubiquitous 50 mM
phosphate buffer. This further cements the need for biologically relevant buffer
concentrations, which can be easily produced without the need for gas sparging.
1.3. Gastrointestinal Simulator, Artificial Stomach
Duodenum, and Other in vivo predictive
dissolution methodologies
As previously discussed, USP-type dissolution apparatuses, do not properly simulate
the gastro-intestinal physiology in a manner that can provide predictive dissolution in
most cases. Due to the void left behind by the USP, several in vivo predictive
methodologies have been created, including: biphasic dissolution, the gastro intestinal
simulator (GIS), the artificial stomach duodenum (ASD), and the TNO GI Tract Model
(TIM). In addition, to the unique apparatuses and methodologies associated with these
technologies, they also may take advantage of biorelevant dissolution media, as
discussed in the previous subsection. Biphasic dissolution attempts to model the
absorption component of dissolution, in order to more accurately predict in vivo
performance, specifically for compounds where permeability predominates: BCS class II
and IV compounds. As seen in figure 1.4, the biphasic system has a double paddle,
similar in shape to a USP apparatus 2 paddle, with an aqueous media on the bottom
(dark grey) and a lower density organic phase, typically octanol, on top (light grey).
Since the interface between the organic and aqueous phases can be easily disrupted, a
predissolved solution of drug is added to the buffer system in the bottom layer. The
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drug concentration is monitored in the both phases until equilibrium is achieved. These
experiments allow for drug absorption to be simulated while using an appropriate
volume of biorelevant media. The GIS is an attempt to create improved IVIVC by
Figure 1.4: Biphasic dissolution schematic
approximating the in vivo conditions in a laboratory bench top setting. The term has
become interchangeable with ASD, as both are similarly set up 18-20. Figure 1.5, below
shows an example schematic of a GIS device. In Figure 1.5, three chambers are show to
represent the first three GI sections: the stomach (orange), the duodenum (cyan) and
the jejunum (blue). The ASD, such as the one used by Polster and Sperry, lacks the final
jejuna compartment 20. For the stomach and the duodenum, there are also secretion
reservoirs which provide dissolution media at a constant rate throughout the course of
the experiment. Each vessel has computer controlled volume and fluid transfer rates to
precisely represent the in vivo conditions. Each vessel utilizes biorelevant dissolution
mediums to create a bulk and local pH that is biorelevant. For this system, the stomach
has an acidic condition and the duodenum and jejunum are closer to neutral pH. For
BCS subclass compounds like BCS IIa and IIb, this may lead to different observed
dissolution behavior than that observed in a conventional dissolution experiment. In a
publication by Matsui, et al., two drugs, one a BCS I drug and one BCS IIb (weak base),
fluconazole and dipyridamole respectively, were compared in a GIS system using varied
gastric pHs, in an attempt to show potential drug-drug interaction between these drugs
and acid-reducing drugs Each panel shows two comparative experiments, one with a
14
Figure 1.5: Gastrointestinal Simulator (GIS) schematic
Figure 1.6: Dipyridamole (a BCS IIb compound) (left) and fluconazole (BCS I) (right) GIS
dissolution; concentration in intestinal regions
gastric pH of 2.0 (closed circles) and one at pH 6.0 (open circles). This study shows that
the extent of dissolution for fluconazole is not affected by gastric pH. However, for
dipyridamole, the concentration in the intestinal region is altered by changing gastric
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pH. This study shows the value added by IVIVC dissolution, not only for differentiating
between drugs, but also the importance of pH on dissolution 18. The final dissolution
apparatus to be discussed is TIM. TIM was designed to simulate the luminal conditions
of the gastrointestinal tract in a multicompartment model. TIM is typically used for
food products but has been applied to pharmaceuticals. In figure 1.7, below is a
schematic for TIM. Compartments of note in Figure 1.7 are A–the gastric compartment;
Figure 1.7: Schematic of the TIM system
C–the duodenal compartment; E–the jejunal compartment, G– the ileal compartment;
and N & O– the absorption components, consisting of a hollow fiber for absorption and
the associated collection of the simulated bioavailable fraction. In comparison to the
GIS/ASD and the biphasic system, TIM takes a lot of the addition components, like
secretion vessels and peristaltic fluid flow, and iterates on them to attempt to . It utilizes
16
tubular flow to attempt to simulate in vivo hydrodynamics. In addition, each the
jejunum and ileum compartments have hollow fiber membranes to provide an
absorptive component.
17
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Chapter 2.
Evaluation of Amorphous Solid
Dispersion Dissolution in Biorelevant
Dissolution Media
2.1. Introduction
Drug molecules with low aqueous solubility and high permeability rates, classified as
BCS Class II molecules, can be further separated by their behavior with respect to pH
into three subclasses: acid (a), bases (b), and neutral (c).1,2 As the extent of ionization
increases across a pH range, the aqueous solubility increases. The active
pharmaceutical ingredient, Compound A, used in this study is a BCS Class IIb drug with
low aqueous solubility (<1ug/mL), high permeability (logP >3, cLogP 4.11) and pKa of
3.93. It is non-ionized at neutral pH (approximately 6.5). Hydroxypropyl
methylcellulose acetate succinate (HPMCAS) is a weak acid polymer exhibiting pH
dependent solubility and dissolution with a pKa of approximately 5 and very low
intrinsic aqueous solubility at low pH. For certain compounds, formulation techniques
are used to increase the solubility of the compound, in order to increase bioavailability.
The solubility enhancement of amorphous forms compared to the crystalline form can
be on the range of 2-fold to over 100-fold.3-6 This enhancement is affected by the
difference between energy states of the crystalline and amorphous forms and the
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changes in free energy due to water sorption.3,6 However, amorphous compounds are
unstable and begin to crystalize over time, losing the solubility enhancement the
amorphous form provides. Thus, crystallization inhibition may be necessary to utilize
the solubility enhancement of amorphous forms. Crystallization can be inhibited with
the formulation of an amorphous solid dispersion. An amorphous solid dispersion is a
mix of a polymer and drug, both in amorphous state. The drug must be soluble in the
polymer of interest for the polymer to impart stability against crystallization.7
Hydrogen bonding between polymer and drug has also been shown to play a role in
crystallization inhibition.8 By preventing crystallization, solid dispersions allow for the
drug to reach supersaturation, a concentration well above the intrinsic solubility of the
crystalline form. The ratio between drug and polymer can be tuned so that drug
dissolution and drug solution stability can be optimized. At high polymer levels, drug
dissolution rates can be increased to the point of being congruent with the dissolution
rate of the polymer and therefore controlled by the dissolution of polymer.9 Promoting
supersaturation and extending the supersaturation are desirable properties of
amorphous solid dispersions.7 HPMCAS has been shown to provide the enhancement
to various drugs.10,11 It remains a significant challenge to identify in vitro dissolution
test conditions that are predictive of in vivo performance. Mudie, et al. reviewed the
physiology of the human gastrointestinal tract to identify parameters relevant to the
development of biorelevant dissolution methodologies including concentrations of bile
salts, ions, lipids, and enzymes that play a role in dissolution and absorption in vivo,
along with pH, viscosity, surface tension, osmolality, buffer type and buffer capacity.12
While a wide range of luminal osmolalities has been reported in the literature12 and is
dependent upon fasted or fed states and location of sampling, a range of approximately
150-300 mOsm/kg would appear reasonable and corresponds to approximately isotonic
conditions and can therefore be considered physiologically realistic (e.g. 150 mM
NaCl).13-15 Typically, conventional dissolution studies are performed in high buffer
media, such as 50mM phosphate buffer, at a pH between 6.5 and 7.0 to ensure robust
analysis with minimal pH changes during dissolution testing. However, in vitro systems
for evaluating formulation differences may be expected to better correlate with in vivo
performance by using buffer concentrations and species reflective of the intestine.
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Bicarbonate is the physiologic buffer of the intestinal tract and is created in vivo by
secretion of bicarbonate ions. These bicarbonate ions are generated by the presence of
carbon dioxide with carbonic anhydrase enzymes in the pancreas and small intestine.
However, in vitro use of low buffer capacity bicarbonate buffer systems is more difficult
to use for routine dissolution analysis. Bicarbonate dissolution systems typically sparge
carbon dioxide or a carbon dioxide: air mixture into solution to maintain the dissolved
carbon dioxide concentration, creating a complex dissolution media and the presence of
dissolved gas. Furthermore, bicarbonate buffer has unique properties that result in a
more complex mass transport and dissolution process.16 As a result of this complexity, a
buffer with similar behavior to bicarbonate buffer is extremely desirable. A method for
determining equivalent phosphate buffer for a physiologically relevant 10.5 mM
bicarbonate buffer has been previously reported for drug molecules in the absence of
excipients.16 Using Krieg, et al. as to provide a starting point, a weakly acidic compound
like HPMCAS, at pH 7.0, the expected equivalent phosphate buffer concentration
should range between 2.5-10 mM. Bicarbonate buffer and its effect on surface pH does
not only affect drug molecules, but can also be useful in evaluating other pH dependent
excipients, mainly pH dependent polymers such as HPMCAS. Some of these polymers
have pH-controlled solubility due to carboxylic acid groups which are non-ionized at
low pH. These polymers can be used as enteric coatings. Enteric coatings can be
applied to drug products to delay drug release until reaching the intestinal tract. A
review by Al-Gousous et al. states that, despite use since before the turn of the 20th
century, disintegration and dissolution of enteric coatings beyond the stomach has not
been well defined.17 The review continues by suggesting the use of bicarbonate buffers
to determine discrepancies between in vitro and in vivo performance of products with
enteric coats.17 Conventional in vitro tests have shown relatively fast disintegration and
dissolution compared to the in vivo processes. However, with appropriate buffer
systems, in vitro systems have shown promise in predicting in vivo performance.18
Bicarbonate buffer has also been shown to provide rank order dissolution evaluation to
discern between differing enteric coats for prednisolone, a BCS Class I drug.19 One
study by Kararli, Kirchkoff and Truelove showed that increasing ionic strength in vitro
caused increased dissolution rate for enteric coated formulations.20 The goal of this
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study is to determine the role of buffer species and concentration, ionic strength, and
pH as part of ASD dissolution both with respect to Compound A and the role of
HPMCAS in determining overall drug dissolution. Our hypothesis is that HPMCAS as a
weak acid determines the overall dissolution of API (Compound A), a weak base, and
that a low buffer capacity phosphate buffer with physiologically realistic ionic strength
will successfully mimic physiologically relevant bicarbonate buffer with a
physiologically realistic ionic strength. Furthermore, a more complete understanding of
the mechanism of dissolution under physiologic conditions will provide greater insight
into in vivo performance of ASDs.
2.2. Materials and Methods
2.2.1. Materials
Active pharmaceutical ingredient (Compound A) solid dispersion were used for all
dissolution experiments. The solid dispersion was formed by dissolving API in a
pH-sensitive polymer matrix using hot-melt extrusion technology; the API was mixed
with HPMCAS (1:3, w/w) for the hot-melt extrusion process. For standard solutions,
analytical grade Compound A was used. All other materials used were of analytical
grade or greater. Purified water was used for all experiments.
2.2.2. Dissolution Experimental Conditions
Dissolution experiments were performed under the conditions shown in Table 2.1.
Phosphate buffer solutions used as dissolution media were prepared using sodium
monobasic phosphate and sodium phosphate dibasic anhydrous to the desired
concentration and initial bulk pH. Sodium chloride was added as needed to adjust ionic
strength. Polysorbate 80 was added to each buffer solution at a ratio of 1.3% w/v. After
addition of polysorbate, the solution was allowed to mix until dissipation of foam.
Addition of polysorbate 80 was necessary to prevent crystallization of drug and ensure
dissolution of drug under physiologic pH conditions where it is non-ionized and
24
therefore very insoluble. Crystalline form solubility in polysorbate 80 concentration
was very low and could not contribute to the extent of the dissolution. All dissolution
experiments were performed with media maintained at 37°C. USP <711> Apparatus 2
was used, and dissolution media volume was fixed at 900 mL with a paddle speed of 50
rpm. Solid dispersion was accurately weighed to achieve target dose of compound A
and added to each dissolution vessel. While monitoring the pH over the course of the
experiment, dilute solutions of hydrochloric acid and sodium hydroxide were used
through manual addition to maintain the pH with 0.1 pH units.
2.2.3. Bicarbonate Buffer
The buffer capacity of an open carbon dioxide system has been described
mathematically as shown in Equation 1.21
𝛽𝑜𝑝 = 2.303[𝐻𝐶𝑂−3 ] (2.1)
Where βop is the buffer capacity of the solution and [HCO3-] is the molar concentration
of bicarbonate.21 The buffer capacity of bicarbonate is typically sufficient to maintain
bulk pH when continuously sparging with carbon dioxide. However, the pH at the
dissolving surface of a particle dictates the dissolution of ionizable drugs and excipients.
At the surface of a dissolving particle or tablet, a pH gradient occurs as dissolving
solute (drug or polymer) alters the pH such that the bicarbonate buffer is unable to
maintain the bulk pH at the surface of the dissolving substance.16,19Bicarbonate buffer
solutions were prepared by continuously sparging a mix of 100% compressed air and
100% dry carbon dioxide (Metro Welding, Ann Arbor, MI), using gas flow controllers
(King Instrument Company, CA, USA) to make the desired bicarbonate concentration in
a 0.9% w/v sodium chloride solution. Throughout the experiment, percentage of
aqueous carbon dioxide and pH were monitored using a CO2 monitor (YSI 8500, Yellow
Springs, OH) and a pH meter (Beckman Φ 40, Brea, CA), respectively. Solid sodium
hydroxide was added to adjust the initial pH. For all dissolution experiments, samples of
approximately 2 mL of media were withdrawn from the vessel and filtered (Millex 1.0
µm glassfiber syringe filter, 25 mm diameter, EMD Millipore, Burlington, MA). The
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filtrate was then diluted at a 1:1 ratio with acetonitrile in an HPLC autosampler vial.
Standard vials were prepared in a similar manner.
2.2.4. HPLC Method
Sample solutions were analyzed by an isocratic reverse phase HPLC method (Agilient
1100 Series, Santa Clara, CA) using an Agilent Zorbax SB-Phenyl column (4.6 x 150mm,
3.5um particles). Mobile phase was prepared at a 36:64:0.15 v:v:v ratio of
acetonitrile:water:85% o-phosphoric acid. The column was maintained at 40°C with a
mobile phase flow rate of 2.0mL/minute. UV detection was performed at 254 nm. A
standard solution was prepared at 0.3mg/mL approximating the final concentration of
sample solutions.
2.2.5. NMR Sample Preparation
Deuterium oxide (D2O) was purchased from Cambridge Isotope Laboratories and was
used as received. 1.7 mm NMR tubes were acquired from Bruker (Bruker Biospin,
Rheinstetten, Germany). Acetonitrile (ACN) was purchased from Fisher Scientific
(Thermo Fisher Scientific, Waltham, MA, USA) and was used as received.
Samples for NMR analysis were prepared using the following workflow. The reason for
utilizing this workflow is discussed in more detail in the discussion section. One mL
samples from dissolution testing were added to HPLC vials. 500 µL of each sample was
transferred to a 96-well, low-volume plate (1.5 mL). Water was removed from the
samples using a GeneVac® EZ-2 centrifugal evaporator (GeneVac Ltd., Ipswich, United
Kingdom) prior to extraction with deuterated phosphate buffer, pH 6.5 acetonitrile
(50:50, v/v) using a Scilogex MX-M microplate mixer (Scilogex, LLC., Rocky Hill, CT).
Using a Gilson® GX-274 liquid handling system (Gilson, Inc., Middleton, WI, USA), 45
µL of solution was then transferred to 1.7 mm NMR tubes (60 µL total volume) in a
SampleJet cassette (Bruker Biospin, Rheinstetten, Germany) for automated NMR
analysis.
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2.2.6. NMR Spectroscopy
All NMR experiments were performed on a Bruker AV-III 500 MHz spectrometer
equipped with a 1.7 mm TCI z-gradient cryoprobe and SampleJet automated sample
changer (Bruker Biospin, Rheinstetten, Germany). 1H NMR spectra were acquired at
298.0 K using the zg30 pulse sequence (Bruker Biospin, Rheinstetten, Germany) at a
pulse width of 13.5 s. 65,536 points were acquired through 320 scans with a spectral
width of 8 kHz, constant receiver gain, an acquisition time of 2 s, and relaxation delay
of 3 s. Data were acquired with TopSpin™ software (Bruker Biospin, Rheinstetten,
Germany) and processed using MestReNova 11.0 software (Mestrelab Research S. L.
Santiago de Compostela, Spain).
2.3. Results and Discussion
2.3.1. Comparison of Conventional Dissolution Media to
Bicarbonate Buffer
Dissolution of the ASD was performed in conventional dissolution media: 50 mM
phosphate buffer, pH 6.8, 200 mM ionic strength; and in 10.5 mM bicarbonate buffer at
two different pH conditions, 7.0 and 6.5 and results are shown in Figure 2.1. The
dissolution of the ASD in the conventional phosphate buffer media was substantially
faster than dissolution in the bicarbonate buffer. In bicarbonate buffer, dissolution did
not reach completion after two hours at either pH condition.
2.3.2. Determination of Equivalent Phosphate Buffer at pH 7.0
As previously discussed in the introduction, the expected equivalent phosphate buffer
concentration for HPMCAS approximating physiologically relevant bicarbonate buffer
at pH 7.0 is between 2.5 and 10 mM. This estimation is based on the low solubility of
HPMCAS and its pKa of approximately 5.16 Using this equivalent phosphate
concentration as a basis, the bicarbonate dissolution profile was compared to three
phosphate concentrations in that range: 2.5 mM, 5.0 mM and 7.5mM, as shown in
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Figure 2.1: Comparison of conventional dissolution media at pH 6.8 (Condition A) to
bicarbonate buffer at pH 7.0 and 6.5 (Conditions B and D, respectively). See Table 2.1 for
full descriptions of each condition
Figure 2.2 (conditions E, G and M, respectively). The profile for 2.5 mM phosphate
buffer was most similar to the bicarbonate buffer in both rate and extent of dissolution.
Two expected equivalent phosphate buffer concentrations were used to further
characterize impact of ionic strength and set of experiments were carried out by
varying ionic strength: 2.5mM and 7.5mM. Under those buffer concentrations, ionic
strength was controlled using varied levels of sodium chloride for ionic strengths
between 50 and 150 mM. Figure 2.3, in the left panel, shows a comparison of 2.5 mM
phosphate buffer at varying ionic strengths to 10.5 mM bicarbonate buffer at 150 mM
ionic strength the right panel compares 7.5 mM phosphate buffer at varying ionic
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Figure 2.2: Comparison of pH 7.0 bicarbonate buffer (Condition B) to varying phosphate
concentrations at pH 7.0, (E: 2.5mM,G: 5mM, K: 7.5mm). See Table 2.1 for full descriptions
of each condition.
strengths to the same 10.5 mM bicarbonate buffer. These data demonstrate the
important role of ionic strength on the extent and rate of drug ASD dissolution. With
increasing ionic strength, the extent of dissolution of drug ASD increases. This effect on
extent of dissolution with increasing ionic strength appears to reach a maximum effect
at 150 mM with little increase in extent of dissolution beyond 100 mM ionic strength, as
shown when comparing Conditions E-G in the right panel of Figure 2.3. Understanding
HPMCAS dissolved in sample solution provides a more clear view of the drug
dissolution behavior in media with differing ionic strength. Several chromatography
approaches such as reverse phase and size exclusion were evaluated to determine
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Figure 2.3: Comparison of bicarbonate buffer (Condition B) at pH 7.0 to 2.5 mM (left) and
7.5mM (right) phosphate buffer at different ionic strengths (left, I: 50 mM, J: 75 mM, K:
100 mM, L: 150 mM; right, C: 40 mM, D: 75 mM, E: 100 mM, F: 150 mM, G: 200 mM) See
Table 2.1 for full descriptions of each condition.
amount of HPMCAS in sample solution dissolved over time. Presence of polysorbate 80
complicated the determination of HPMCAS levels using High Performance Liquid
chromatography, hence NMR analysis was used. The dissolution experiments were
conducted in water which can reduced the sensitivity of NMR analysis and introduces
higher noise. Therefore, water was removed from the samples using a centrifugal
evaporator and after water removal extraction was performed with deuterated
phosphate buffer, pH 6.5 /acetonitrile (50:50, v/v). Figure 2.4 shows that with lower
ionic strength (75mM versus 150 mM), there is decreased dissolution rate of HPMCAS
and typically reduced drug dissolution. The dissolution rate of HPMCAS is decreased at
lower ionic strength, resulting in a reduced extent of dissolution for drug and HPMCAS.
The decreased drug dissolution may be due in part to a lower concentration of
HPMCAS dissolved in solution, thus reducing the precipitation inhibition effect that
HPMCAS has on the solution and drug. Using equal ionic strengths in both buffer
systems is important to ensuring an accurate determination of equivalent phosphate.
At pH 7.0, the dissolution rates of both drug and HPMCAS are most similar to the
bicarbonate buffer system with 2.5 mM phosphate buffer and 150 mM ionic strength.
This equivalent buffer concentration is consistent with the dissolution of the low
solubility, weak acid HPMCAS.
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Figure 2.4: Comparison of HPMCAS and Compound A Dissolution at pH 7.0. Condition
B is 10.5mM bicarbonate buffer with 150 mM ionic strength. Both conditions J and L are
2.5 mM phosphate buffer with varied ionic strengths: 75 mM for Condition J, 150 mM for
Condition L. See Table 2.1 for full descriptions of each condition.
2.3.3. Determination of Equivalent Phosphate Buffer at pH 6.5
HPMCAS and drug dissolution was also determined at pH 6.5. These results are shown
in Figure 2.5. As with pH 7.0, the dissolution rates at pH 6.5 of both drug and HPMCAS
are comparable between the bicarbonate buffer system and 2.5 mM phosphate buffer
with 150 mM ionic strength. This equivalent buffer concentration is also consistent
with the dissolution of the low solubility, weak acid HPMCAS.
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Figure 2.5: Comparison of HPMCAS and Compound A Dissolution at pH 6.5. Condition
M is 10.5 mM bicarbonate buffer with 150 mM ionic strength. Condition N is 2.5 mM
phosphate buffer with 150 mM ionic strength. See Table 2.1 for full descriptions of each
condition.
2.3.4. Discussion
These results demonstrate that conventional in vitro dissolution conditions with high
buffer capacity phosphate can substantially increase the dissolution rate and extent of
dissolution for ASDs utilizing HPMCAS. When compared to a biorelevant buffer system
like bicarbonate, the dissolution rate of the model drug-HPMCAS ASD is substantially
higher in conventional media at the same pH conditions. Additionally, the ionic
strength of solution also affects the rate and extent of dissolution of HPMCAS and drug
in weakly buffered media. This is likely due in part to the enhanced solubility of
HPMCAS which can inhibit precipitation of the metastable amorphous form drug
present in the ASD and thus provides solubility enhancement above the intrinsic
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solubility. These results are consistent with the hypothesis that HPMCAS is dictating
the overall dissolution rate of drug-HPMCAS granules in physiologically relevant
buffer. The equivalent phosphate buffer for the ASD determined was 2.5 mM for both
pH 6.5 and pH 7.0 conditions and 150 mM ionic strength, consistent with the expected
equivalent phosphate concentration for low solubility, weak acid HPMCAS polymer.
For this formulation, congruent dissolution rates were observed between the polymer
and drug under isotonic conditions. Drug dissolution therefore appears to be controlled
by the dissolution of HPMCAS.
2.4. Conclusions
These results emphasize the value of in vivo relevant media in conducting mechanistic
in vitro testing. The dissolution rate of the model drug-HPMCAS ASD is substantially
higher in conventional media compared to physiologically relevant bicarbonate buffer
system. Ionic strength also plays an important role in the rate and extent of dissolution
of HPMCAS and drug in weakly buffered media. Under biorelevant conditions utilizing
either physiologically relevant bicarbonate buffer concentration or low buffer capacity
phosphate buffer at approximately isotonic conditions (150 mM ionic strength) drug
dissolution is controlled by the dissolution of HPMCAS.
Further evaluation of optimal polymer to drug ratios could be explored using
bicarbonate buffer or its equivalent phosphate buffer. These results are promising for
improved evaluation of ASDs and could provide a means to predict an optimal ASD
formulation during the pre-clinical phase of development.
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Chapter 3.
Gastro-Intestinal Simulator-2 Device
Design and Method Validation
3.1. Introduction
For oral drug formulations, the efficacy of the formulation on the individual is
dependent on many physiological processes and variables. For most drug products, the
formulation must disintegrate, undissolved mass must empty from the stomach and
into the upper Gastrointestinal (GI) tract, the drug must dissolve and then absorb across
the intestinal wall to reach systemic circulation.1 In addition, the GI fluid is a complex
multi-component system.2,3 One of the difficulties in a pre-clinical setting is capturing
the relevant processes and variables in order to relatively rapidly evaluate formulations.
Despite understanding of relevant processes, conventional in vitro methods only
capture part of one of these processes by performing dissolution at one pH, without any
other processes acting on the formulation. Therefore, in order to produce relevant
dissolution data in vitro for the goal of producing predictions of in vivo performance,
the processes involved in vivo must be considered when designing a new dissolution
device. These processes should be selected based on the drug molecules physical
properties, such as using their BCS class and subclass as a guide, in order to provide the
optimal test. In this work, the consideration of these processes is discussed and
examined when designing a four-compartment dissolution device4,5, the
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Gastro-Intestinal Simulator-2 (GIS-2). The USP-2 dissolution device is ubiquitous in the
dissolution field. This dissolution technology is frequently used for quality control
applications, where simplicity and consistency of results is more important than in vivo
relevance. The system can be used to evaluate the effect of variations in manufacturing
conditions on in vitro performance. It is also part of in vitro testing necessary for
waivers for bioequivalence studies for immediate release products.6 However, for
molecules that exhibit pH-dependent solubility, the shift in pH from the stomach to
small intestine is relevant to their dissolution.5 Thus, a dissolution technology for
evaluation of molecules requires a change in pH. A change in pH can be achieved by
multiple routes, by adjusting the pH of the media in a single vessel with the addition of
sodium hydroxide (either solid or solution)7,8 or a highly concentrated buffer
solution8-10, or by transferring fluid between compartments.11-25,29 Fluid transfer
between compartments, not only allows for the pH-shift to occur, but also the gastric
emptying process can occur in a way that simulates the in vivo process. A variety of
multi-compartmental dissolution devices exist and have been shown to be a valuable
piece of a pharmaceutical scientist’s toolkit in formulation design, troubleshooting and
optimization. These devices include: the TNO TIM-111-13, the artificial
stomach-duodenum (ASD)14-17, the Golem apparatus18, and the Gastro-Intestinal
Simulator (GIS)19-22 and other un-named systems based on modified USP dissolution
apparatuses.23-25 These systems range in design philosophy from complex systems
attempting to directly mimic the physiologic conditions (TNO TIM-1) and systems that
try to emulate in vivo dissolution conditions while maintaining a simple easy-to-use
dissolution system that can be run multiple times in one day by a single analyst
(GIS/ASD). For the sake of this work, the original GIS, or GIS-1, is examined and used as
a basis for designing GIS-2. One necessary decision for the design of GIS-2 is utilizing
recent research on the hydrodynamics of the gastrointestinal tract. Lindfors, 2015
showed that hydrodynamics in the small intestine are not a critical factor for
micronized particles or disaggregation of drug particle aggregates.26 However, GI
hydrodynamics factor into disintegration of large particles and tablets.27 The shear rate
is also important for large non-micronized particles dissolution as shear effect increases
with increasing particle size.29 Lastly, shear has been shown to act as an enhancement
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to mass transfer beyond pure diffusion. This enhancement can be applied to mass
transport equations with use of the Sherwood number. The Sherwood number is a
dimensionless number that is the ratio between total mass flux from the solid particle
surface and flux from that solid by pure diffusion. In terms of conventional equations
used for estimating drug dissolution, the Sherwood number can also be used to describe
the ratio between particle radius and diffusion layer thickness, these equations are
compared in Equation 3.1.
𝑑𝑚
𝑑𝑡 = 𝑆ℎ(4𝜋𝑟)𝐷Δ𝐶 (3.1)
Where dm/dt is the change in mass of an individual particle, Sh is the Sherwood
number, r is the particle radius, D is the diffusion coefficient of the drug molecule and
ΔC is the difference in concentration between the particle surface (saturation) and the
bulk solution. Per the work of, Wang and Brasseur the enhancement from pure
diffusion can be described as ΔSh units for confinement, shear and convection effects,
as shown in Equation 3.2.30-32
𝑆ℎ = 1 + Δ𝑆ℎ𝑐𝑜𝑛𝑓 𝑖𝑛𝑒 + Δ𝑆ℎ𝑠ℎ𝑒𝑎𝑟 + Δ𝑆ℎ𝑐𝑜𝑛𝑣𝑒𝑐𝑡𝑖𝑜𝑛 + … (3.2)
where ΔShconfine is the enhancement due to the confinement effect, ΔShshear is the
enhancement due to shear on the fluid surround the particle and ΔShconvection is the
enhancement due to convective forces. For particles of 100 µm diameter, the
approximate Sherwood number is in the range of 1.4-4.2 under increasing shear rates.30
In addition to shear effects on dissolution, another consideration for hydrodynamics is
maintain well suspended particles. Dissolution can be unintentionally inhibited if
particles are not well suspended and are stationary on the base of the dissolution vessel.
This also alters the solution homogeneity and prevents accurate prediction of
dissolution due to inconsistent undissolved particle transfer between vessels. Hydrofoil
impellers (or hydrofoils) are axial flow impellers that generate particle lift by generating
turbulent eddies on the base of vessel.33-36 For industrial reactor applications,
hydrofoils are a common choice for suspended solid particles and are a good fit for a
dissolution device for maintain particle suspension.
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3.2. Materials and Methods
3.2.1. Materials
All materials were of analytical grade or higher, unless otherwise specified. Acetonitrile
for HPLC analysis was HPLC Grade (Fisher Scientific) and trifluoroacetic acid was
LC/MS-grade (Sigma-Aldrich, St. Louis, MO).
3.2.2. GIS-1 Method Optimization
GIS-1 Method
GIS-1 is an existing device described in literature, Throughout the optimization stage,
the method was in a state of flux to find the optimal method. Listed are initial and final
methods to represent the improvements made over the course of the optimization. For
any deviations from these two methods, a note has been made in the results section to
address those deviations. Initial and final methods are described in Table 3.1, below.
3.3. Determination of the Critical Micellular
Concentration of Sodium Dodecyl Sulfate at pH
2.0 with Ibuprofen
Solutions of varying sodium dodecyl sulfate (0-8 mM) were prepared in 0.01N
hydrochloric acid. Solution was added to a scintillation vial in triplicate and ibuprofen
was added in excess. Control solutions of ibuprofen without SDS were also prepared in
triplicate. Solutions were mixed in a shaker bath at 37C for 24 hours. After 24 hours had
elapsed, an aliquot of the solution was removed and filtered. Filtered solution was
analyzed by HPLC. CMC was determined by the calculating the intercept of the control
concentration with the linear regression of all solutions that showed an increase in
concentration, using Microsoft Excel (Microsoft, Redmond, WA).
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Parameter Original Condition Final Condition
Stirring Conditions
Stomach Stirring 50 RPM with Burst
Mixing at 500 RPM
every 26 seconds
250 RPM constant
Duodenum Stirring 50 RPM with Burst
Mixing at 500 RPM
every 26 seconds
120 RPM constant
Jejunum Stirring 100 RPMwith stir plate 75 RPM
Initial Vessel Conditions
Stomach Initial
Medium
50 mL of 0.01N Hy-
drochloric Acid & 250
mL of purified water
(300 mL total)
50 mL of 2mM SDS
in 0.01N Hydrochloric
Acid & 250 mL 2mM
SDS in water (300 mL
total)
Stomach Secretion
Medium
0.01N Hydrochloric
Acid
2mM SDS in 0.01N Hy-
drochloric Acid
Duodenum Initial
Medium
50 mL of 50 mM phos-
phate buffer at pH 7.0
50 mL of 50 mM phos-
phate buffer at pH 6.5
Duodenum Secretion
Medium
100 mM phosphate
buffer at pH 7.0
100 mM phosphate
buffer at pH 7.0
Jejunum Initial
Medium
Empty 100 mL of 50 mM phos-
phate buffer at pH 6.5
Other Experimental Conditions
Jejunum Beaker Shape 1 L low form Pyrex
beaker
900 mL USP-2 Round
Bottom Water Jacketed
Vessel
Jejunum Temperature
Control
Manually monitored
while heated on heated
stir plate
Controlled by circulat-
ing water bath
Sampling volume 500 µL sampled,
centrifuged and su-
pernatant diluted for
HPLC analysis
1.5 mL filtered and di-
luted for HPLC analy-
sis
Media Replacement No Yes, Replaced Sampled
volume with secretion
media
Stomach VolumeMain-
tained
No Yes at 10 mL
Table 3.1: Comparison of pre-optimization and post-optimization parameters for GIS-1
experiments. 42
3.4. Just Suspended Speed Determination
Just suspended speed was performed based on the procedure originally described by
Zwietering and modified by Ayranci and Kresta.36,37 The water bath was removed and
the vessels were elevated using a lab jack. Normal stirrer clearance was checked. The
water bath was removed to allow for better visibility of the base of the vessels.
Saturated ibuprofen solution was introduced to the vessel at room temperature. A
known volume of ibuprofen suspension was introduced to the vessel. The stir speed
was increased incrementally, allowing one to two minutes to reach steady state. After
this time period, the bottom of the vessel was observed for about 30 seconds. The speed
was increased until no particle was observed to be stationary on the base of the vessel.
This procedure was repeated at three volume conditions in the stomach and two in the
duodenum. Four observers were used to increase sample size and to verify the results.
The just suspended speed was then averaged for the sample group and rounded up to
the nearest 10 RPM.
3.5. Apparent Sherwood Number/Mass Transfer
Enhancement
3.5.1. Particle Size Distribution
Particles used in the suspension for the dissolution test were viewed via brightfield
microscopy. The particles were viewed through polarized light and digital images were
taken. Images of ibuprofen particles were then processed using ImageJ (NIH, Bethesda,
MD). Based on the rectangular dimensions of the particles, the third dimension was
estimated by taking half of the smallest dimension and multiplying it by the two visible
dimensions to calculate the particle volume. The effective spherical particle size was
then estimated based on this volume. A particle size distribution was generated based
on the effective spherical particle sizes observed across observations.
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3.5.2. Dissolution Data
In order to properly predict dissolution in the GIS using mass transport models, an
apparent Sherwood number was determined. Ibuprofen suspension was introduced to
0.01N hydrochloric acid at the appropriate volume for the vessel and the media was
stirred at the determined just suspended speed. Manual samples were taken at regular
intervals, aliquoting 1.5 mL from each vessel. Aliquots were filtered through a 0.45 um
syringe filter, discarding the first 0.5 mL. Remaining filtrate was diluted as necessary for
HPLC analysis. Media removed from each vessel was replaced with appropriate
secretion media to maintain volume.
3.5.3. Apparent Sherwood Number
Using the experimental data, the apparent Sherwood number was calculated, using
equation 3.1. The predicted dissolution was performed post hoc and fit to the observed
dissolution data by varying the Sherwood number to reduce absolute residuals.
3.6. GIS-2 Device & Dissolution Method
3.6.1. 3D Print Material & Tubing Partitioning Study
One cm diameter spheres were printed on a Stratays J750 3D printer (Startasys, Eden
Prairie, MN) using Veroclear transparent photopolymer. Spheres were dried at 105C
overnight to ensure all volatile material had been removed. After allowing to cool to
room temperature in a desiccator, the spheres were weighed and the diameter was
recorded using calipers. One sphere was added to an ibuprofen solution of known
concentration. The spheres were stirred at 37C for 72 hours, taking timepoints at 12, 24,
48 and 72 hours. Samples were assayed as described above. After 72 hours, the spheres
were removed and dried in the oven again overnight. Spheres were weighed to
determine any weight increases. This procedure was also applied to tubing for the
Ismatec pumps, with the modification of only 72-hour time points being taken.
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3.6.2. Device
The GIS-2 is a computer-controlled, four-vessel dissolution device for testing oral
formulations. The four vessels represent the stomach, duodenum, jejunum, and ileum.
The conditions of the experiment can be adjusted, including initial volumes, stomach
emptying profile, secretion rates, temperature, pH, buffer capacity and ionic strength.
pH is continuously monitored throughout the experiment. The vessels are flat-bottomed
cylindrical glass jacketed vessels. The vessels are mixed using top-down stirring,
controlled by digital motors (Myostat Motion Control Inc., Newmarket, ON Canada).
The stirrers use appropriately sized 3-blade hydrofoils (Manufacturer, Location).
3.6.3. Method
The devices was controlled by software developed in Labview (National Instruments,
Austin, TX). Screenshots of the GUI of the GIS-2 software can be found in Appendix A,
along with the operating procedure. Stirring was maintained at speed, cycling between
a lower speed to suspend most particles, with a one second burst, every sixty seconds to
re-suspend any particles that may have settled to the bottom of the vessel. All fluid
transfer was controlled by Ismatec Reglo ICC peristaltic pumps (Cole-Parmer GmbH,
Wertheim, Germany). Pumps were standardized with water on day of analysis before
analysis. Initial conditions can be found in Table 3.2. The stomach emptied from 300
mL, initially, to 75 mL with first-order kinetics (t1/2: 30 min). Volume was maintained
at 50 mL in the duodenum and jejunum. The ileum accumulated all excess volume to
maintain the first three vessels. After the stomach reached 75 mL, the experiment
continued for one hour, with secretions only, with the stomach, duodenum, and
jejunum volumes held constant. Formulations were pre-disintegrated in the stomach,
by stirring at 120 RPM for 10 minutes, before fluid transfer was initiated.
Manual samples were taken at regular intervals, aliquoting 1.5 mL from each vessel.
Aliquots were filtered through a 0.45 um syringe filter, discarding the first 0.5 mL.
Remaining filtrate was diluted as necessary for HPLC analysis. Media removed from
each vessel was replaced with appropriate secretion media to maintain volume.
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Vessel Initial Volume and
Media
Stir
Speed
(RPM)
Burst
Speed
(RPM)
Secretion Buffer
and Rate
Stomach 300 mL: 250 mL of
2mM SDS 50 mL of
0.01N HCl w/ 2mM
SDS
120 240 2.5 mL/min: 50
mL of 0.01N HCl
w/2mM SDS
Duodenum
& Jejunum
50 mL of 50 mM Phos-
phate Buffer pH 6.5
175 350 1 mL/min: 100
mM Phosphate
Buffer pH 6.5
Ileum 250 mL of 50 mM
Phosphate Buffer pH
6.5
75 150 NA
Table 3.2: Standard GIS-2 media and stirring conditions for experiments.
3.6.4. Stomach Emptying Rate & Maintain Phase Validation
With the introduction of new stomach emptying methods and the ability to maintain
stomach volume post-gastric emptying, those new processes required validation. For
the new software, three emptying profiles were implemented: 1st order, Weibull and
User-Defined. The pre-defined profiles are shown for a 300 mL starting volume in
Figure 3.1. In order to validate the emptying profiles, each profile (and the maintain
phase) was appropriately setup in the software and each vessel was replaced with an
appropriate vessel in order to monitor. The stomach, duodenum and jejunum manually
monitored gravimetrically and the ileum was monitored using a graduated cylinder.
The initial volume of the stomach was reduced from the typical starting volume to 250
mL due to balance limitations, the duodenum and jejunum were at 50 mL. The
gravimetrically monitored vessels were tared before initializing the pumps and their
weight was recorded incrementally and concomitantly from stomach to ileum. The
difference from tare weight was then used to calculate the observed volume and how
the observed volume deviated from the expected volume.
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Figure 3.1: Standard GIS-2 media and stirring conditions for experiments.
3.6.5. Titration
Predictions
Predictions for titration methods were generated using MatLAB (Mathworks, Natick,
MA). Using the Henderson-Hasselbach equation and maintaining constant volume in
the duodenum vessel, total buffer concentration, individual buffer species
concentrations and pH were estimated across small time increments (< 1 second). Based
on those inputs the amount of titrant was calculated, depending on the method being
tested. Code can be found in Appendix B.
Experimental
Titration methods were tested by calibrating the first unused pump channel and
priming it with 0.01N sodium hydroxide. Stomach and duodenum conditions were set as
described in Table 3.2, with the exception of the duodenum media and secretion which
47
were 5 mM and 50 mM phosphate buffers, respectively. Throughout the experiment, pH
was monitored and recorded. An 800 mg ibuprofen tablet was introduced to the
stomach at the beginning of the experiment to simulate a weakly acidic drug.
3.6.6. HPLC Method
Filtered and diluted samples were analyzed by an isocratic reverse phase HPLC method
(Agilient 1100 Series, Santa Clara, CA) using an Agilent C-18 column (3.5µm x 4.6µm x
150mm). Mobile phase was a 60:40 mix of acetonitrile:water with 0.1% trifluoroacetic
acid. The column was maintained at 40°C with a mobile phase flow rate of
1.0mL/minute. UV detection was performed at 220 nm. A standard curve was prepared
bracketing the sample solutions.
3.7. Results
3.7.1. GIS-1 Method Optimization
Concerns for Requiring Method Optimization
Figure 3.2 shows the total mass dissolved in the GIS-1 following a 1-hour experiment.
Following 1 hour about 40% of the total dose was dissolved in the system. This
experiment showed poor mass recovery in the system and required improvements in
order to ensure repeatable and quality data is generated when using GIS-1. This was
also necessary to determine what design considerations are needed when designing a
next generation device, where improvements can be made.
The first improvement was extending the length of the experiment out to two hours.
This was initially achieved in GIS-1 by preventing the volume in the stomach to fall
below 10 mL by raising the height of the transfer tube. This was later done by updating
the software of the GIS. Next, the sampling procedure needed to be changed. The
previous method allowed for inconstant results to be obtained due poor pelletizing of
centrifuged samples. If a small drug particle was transferred to the HPLC vial for
dilution, results were skewed. To prevent drug particles from being dissolved in the
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Figure 3.2: Performance of GIS-1 dissolution of an 800 mg ibuprofen tablet using pre-
existing methods.
HPLC vial, a 1.5 mL sample was removed and filtered. To compensate for the larger
volume removed, equivalent media was replaced into the dissolution vessels to ensure
consistent volumes. Third, the pumps were rearranged and tubing was cut to limit
particle settling in the transfer tubing lengths. Additionally, transfer pumps and the
stomach and duodenum vessels were rinsed after analysis to capture any undissolved
drug for mass balance. Next, the jejunum vessel was replaced with a jacketed USP-2
vessel. This helped with maintaining volume and temperature in the jejunum with the
assistance of a lid and the recirculating water bath. Lastly, the pump procedure was
changed in updated software to be based on a known number of revolutions of the
pump and the measured mass of water transferred. This ensures that the pumps are
pumping at the correct volumetric flow rate instead of relying on the previous
calibration factor to estimate how much volume was transferred. The length of the
pre-calibration pump priming cycles and the calibration cycles and calibration speeds
were also adjusted to improve calibration. A summary of purge and calibration
conditions can be found in Table 3.3.
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Pump Type Purge Conditions Calibration Conditions
Secretion Pump 45 RPM for 10 min 10 RPM for 3 min
Transfer Pump 90 RPM for 10 min 50 RPM for 3 min
Table 3.3: Summary of pump purging and calibration conditions.
3.7.2. Determination of the critical micellular concentration of
sodium dodecyl sulfate at pH 2.0 with Ibuprofen
Figure 3.3 shows change in ibuprofen concentration with increasing concentrations of
sodium dodecyl sulfate. There was inconclusive literature data on the CMC of SDS at
pH 2. Surfactant was explored because during the disintegration of the ibuprofen tablet,
solid adhesion was absorbed on the glass walls of the stomach beaker. This adhesion
was severe enough to make the glass beaker nearly opaque. This was another suspected
source of loss of ibuprofen to the system. By adding surfactant, drug wetting was
improved slightly and the solid adhesion to the walls of the beaker was greatly reduced.
The CMC was determined to be the SDS concentration when the linear regression of
the elevated ibuprofen concentration intersects the concentration of the control. This
intercept was 3.060 mM of SDS. In order to ensure the media remained below the CMC
while preventing solid adhesion to the walls of the vessels, 2 mM SDS was selected as
an acceptable concentration of SDS.
3.7.3. GIS-1 Hydrodynamics
Just Suspended Speed in GIS-1 Stomach and Duodenum
Just suspended speed was determined by addition of ibuprofen particles to GIS-1
vessels. Table 3.4 summarizes the results of the just suspended speed experiments in the
GIS-1 stomach and duodenum vessels. In order to ensure full suspension of particles,
the stir speeds can be during operation of the GIS-1.
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Figure 3.3: Ibuprofen concentration when increasing sodium dodecyl sulfate in order to
determine the critical micellular concentration (CMC). CMC was determined to be the
SDS concentration when the linear regression of the elevated ibuprofen concentration
intersects the concentration of the control (the intrinsic solubility)
Volume (mL) RPM SEM
Stomach (n=3)
300 mL 250 5.6
200 mL 238 11.5
100 mL 242 16.8
Duodenum (n=4)
50 mL 118 4.0
25 mL 111 8.1
Table 3.4: Summary of the just suspended speed observations and the standard error of
the mean for the replicates.
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3.7.4. GIS-1 Post-Method Optimization
Following the above optimizations on GIS-1, the results of an 800 mg dissolution
experiment can be seen in Figure 3.4. The experiment resulted in 90% of the dose
dissolved in the GIS-1 vessels after two hours. This gave confidence in the entire
procedure, which could be transferred over to the new device.
Figure 3.4: Dissolution of 800 mg ibuprofen tablet in GIS-1 after method optimization.
This also includes pH monitor of the duodenum and jejunum compartments
3.8. GIS-2 Design
3.8.1. Vessel Design
Initial vessels were rapid prototyped using 3D printing. To validate the design
decisions, dissolution experiments were attempted in the 3D printed vessel designs, but
had aberrant results. In order to determine the cause, partitioning studies were
performed on the 3D printing material.
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3D-Print Prototypes & Partitioning
Table 3.5 summarizes the LogD of ibuprofen in the 3D print material. Since ibuprofen
had high permeability in the 3D print material it was unsuitable for use in GIS-2 and
glass was chosen as a replacement material
pH LogD
2.0 1.94
6.5 0.37
8.0 -0.37
Table 3.5: Summary of pH-dependent LogD of ibuprofen in the Veroclear 3D print mate-
rial. All items in this table are unitless
Glass Dimensions
The ileum vessel was replaced with a glass water-jacketed USP-2 vessel. For the
stomach and the vessels were custom water-jacketed flat-bottomed vessels with
dimensions described in Table 3.6. These dimensions are close to the prototypes and
were used for the remainder of experiments. For the stomach and ileum, 3-blade
two-inch diameter stainless steel hydrofoils were selected for mixing and for the
duodenum and jejunum 3-blade one-and-one-half-inch diameter stainless steel
hydrofoils were selected.
Vessel Diameter Minimum Height
Stomach 74 mm >100 mm
Duodenum 46 mm > 40 mm
Table 3.6: Dimensions of GIS-2 vessels. Minimum height is listed for each vessel type
3.8.2. Vessel Hydrodynamics
Following the finalization of the vessels, the just suspended speed was determined for
the three vessel types. The results of the just suspended speed study are shown in both
stirring directions in Table 3.7. Since clockwise stirring had lower just suspended
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speeds, the vessels were stirred in a clockwise direction. After determining the just
Vessel Counter-Clockwise Clockwise
Stomach (300 mL) 120 RPM 160 RPM
Duodenum/Jejunum (50 mL) 175 RPM 220 RPM
Ileum (250 mL) 75 RPM N/A
Table 3.7: Summary of just suspended speed in GIS-2 for all vessels
suspended speed, the apparent Sherwood number was determined for these stirring
speeds at two different solution volumes. The results of the apparent Sherwood number
estimation are shown in Table 3.8. These apparent Sherwood numbers can be used to
predict dissolution in the GIS-2 system.
Vessel and Volume (mL) Apparent Sherwood Number
Stomach – 300 3.75
Stomach – 100 2.8
Duodenum – 50 1.33
Duodenum – 25 3.33
Table 3.8: The apparent Sherwood number for ibuprofen suspension dissolution deter-
mined in each dissolution vessel at high and low volume. The apparent Sherwood num-
ber is a unitless quantity.
3.8.3. Tubing Selection
In order to achieve faster stomach emptying rates and the additional secretion rates of
three vessels with secretion, the GIS-2 device needed new tubing. Three tubing types
were evaluated for drug partitioning, Tygon HC, Pharmed and Viton. The results are
summarized in Table 3.9. The Viton tubing had the lowest partitioning coefficient and
was selected at its greatest available inner diameter for use in the transfer pumps. In
order to limit the length of tubing exposed to drug solution, stainless steel tubing was
cut to bridge the distance between the vessels and the pumps. For the secretion
channels, stainless steel tubing was used for the length inside the vessel, as no drug
should be exposed to the secretion tubing.
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Tubing Partition Coefficient per Length of Tubing log[(ug/cm) / (ug/mL)]
Tygon HC 1.62
Pharmed 1.11
Viton 0.75
Table 3.9: Length normalized partition coefficient for the three proposed tubingmaterials.
Partition coefficient is a unitless quantity.
3.8.4. Stomach Emptying Rates/Pump Validation
Stomach emptying rates needed to be validated as some issues in GIS-1 were related to
incorrect calculation of emptying rates. Three gastric emptying profile types were
validated: 1st order, Weibull and User-Defined. The volume in each vessel was observed
over the course of at least 60 minutes and compared to the theoretical values. The
residuals of each vessel were also calculated. The observed profile and residuals for first
order, Weibull Mean and User-Defined are seen in Figures 3.5, 3.6 and 3.7, respectively.
The user-defined gastric emptying profile that was input into the software can be found
in Appendix 3. All 3 methods lacked any systematic issues and any deviation from
theoretical volume is likely related to error in determining the calibration factor for the
pumps.
Figure 3.5: With a gastric emptying profile of 1st Order, 30 minute half emptying time,
the Observed Volume over time in the GIS-2 Vessels compared to the theoretical volumes
(left) and the residuals of the observed volumes for each vessel compared the theoretical
volumes (right)
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Figure 3.6: With a gastric emptying profile the Weibull Mean (ν=39.4; β=0.81), the Ob-
served Volume over time in the GIS-2 Vessels compared to the theoretical volumes (left)
and the residuals of the observed volumes for each vessel compared the theoretical vol-
umes (right)
Figure 3.7: Using a user-defined gastric emptying profile, the Observed Volume over time
in the GIS-2 Vessels compared to the theoretical volumes (left) and the residuals of the
observed volumes for each vessel compared the theoretical volumes (right)
3.8.5. Titration
Titration is required to maintain bulk pH in the duodenum vessel when lower buffer
concentration media was used. In order to determine the best method for maintain pH,
three methods were proposed: constant titrant infusion, titrant bolus and a hybrid of
the two, where constant titrant infusion occurs, and if the pH falls below a
recommended pH a bolus addition is triggered. A simulation of the bolus method is
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shown in Figure 3.8. In implementation, despite being the most complex, the hybrid
Figure 3.8: Simulated pH for stomach and duodenum with titration maintain pH in the
duodenum. pH in the duodenum ismaintained between 5.5 and 6.0 during the simulation.
solution allowed for slow constant infusion of titrant once below a set-point to maintain
pH. As necessary, the bolus addition allowed the bulk pH to be recovered if the infusion
was unable to maintain bulk pH. To test this titration method GIS-2 dissolution
experiment was performed with an 800mg ibuprofen tablet and a Weibull Mean gastric
emptying profile. The pH data for the stomach and duodenum vessels is shown in
Figure 9. The duodenum pH profile resembles the predicted scheme as shown in Figure
8. The variations in the first 10 minutes is likely due to non-instantaneous pH readings
and rapid acid flux in from the stomach causing the titration system to be unable to
maintain pH as effectively as needed. Also, the calculations in the GIS-2 software to
predict acid flux into the duodenum do not account for undissolved ibuprofen molecules
dissolving in the media and adding protons to solution. However, this process did
maintain pH as intended and is an acceptable titration function for the GIS-2 software.
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Figure 3.9: Stomach and Duodenum pHmeasured in GIS-2 with hybrid titration. Weibull
mean gastric emptying profile.
3.9. Discussion
Multi-vessel and pH-shift dissolution studies have proven to be a good tool for in vitro
evaluation of oral formulations. However, the adaptation of the artificial-stomach
duodenum into the GIS-1 required some changes to the system that were not originally
planned. When first working with the GIS-1 system, there were a myriad of problems
with repeatability and ease of analysis. In order to design a new system, it was
necessary to determine what issues were inherent to the system and which were only
experimental issues that rose from tribalistic learning passed from one analyst to the
next. Simple method refinements (Tables 3.1 & 3.2) removed inconsistencies in sampling
and vessel volume control and allowed for more consistent results and improved mass
recovery (Figures 3.2 & 3.4). In order to prevent drug loss to the vessel walls, accurate
measurement of the CMC of SDS was required to prevent solubility enhancement due
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to micelles (Figure 3.3). The addition of surfactant to gastric fluid quantitively decreased
the amount of undissolved drug that remained in the stomach vessel at the end of the
experiment. However, the physical constraints of the GIS-1 device limited further
refinement and improvements. Thus, with an established method on GIS-1 in place, the
design of GIS-2 could move forward. GIS-2 was developed using 3D printing of rapid
prototypes, in order to visualize and test the dimensions. Following aberrant
dissolution experiments, the partitioning of the 3D print material was determined and
the 3D print material was deemed unsuitable for future experiments (Table 3.5). For this
reason, GIS-2 vessels were fabricated out of glass with similar dimensions as those
prototyped (Table 3.6). Glass allowed for easier observation of the system and assured
no drug partitioning into the vessels. With the vessels and stirrers in place,
hydrodynamics in the vessels could be determined. First, the just suspended speed for
an ibuprofen suspension was determined (Table 3.7). This ensures that particles are
well-suspended in the vessel fluid, without excessive stirring. However, these stir
speeds alone do not provide necessary information to predict dissolution in the system.
In order to predict dissolution, the mass transfer enhancement, or Sherwood number,
was determined (Table 3.8). This Sherwood number is purely empirical and is for the
particle size used in the determination but should provide a good starting point for
estimating dissolution in the system. With the vessels and stirring in place and
characterized, the remainder of the system needed design, evaluation, and validation.
The new software to control the GIS-2 was developed to add new functions to the
system. The first was the addition of new emptying profiles. In order to accommodate
faster emptying profiles and prevent solid drug particles from clogging transfer tubing,
larger tubing for the pumps were selected. In order to ensure lack of drug loss, three
tubing materials were selected based on their available internal diameters and chemical
compatibility. These tubing materials were tested for drug portioning using ibuprofen
and the Viton material was selected based on the lowest partitioning coefficient (Table
3.9). With tubing selected, the emptying profiles could be validated. Since the new
software for GIS-2 was built without using previous versions of the software all
emptying profile types were validated. Three emptying profiles were present in the new
GIS-2 software: 1st order, Weibull profile, and user-defined. Emptying profiles were
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validated by measuring the volume in the vessels gravimetrically, by mass difference.
These volumes were compared to theory and were assessed for any systematic issues
(Figures 3.5-7). Any deviations from theoretical volumes were negligible and were
likely due to small errors in the accuracy in determining the calibration factor and not
related to the implementation of the emptying profiles in the software. Lastly, titration
functions were added to the software, in order to allow for lower buffer concentrations
while maintaining the pH of the bulk solution. The final titration method selected uses
a hybrid of constant titrant addition and small volume instantaneous titrant additions to
maintain the pH within a set range (figures 3.8 & 3.9).
3.10. Conclusions
This work set out to improve upon the existing GIS-1 dissolution device. In order to
improve upon the actual device, the cause of perceived issues with the device were split
into two categories, method-based and device-based. Once the issues were categorized
both method and device improvements could be made. These improvements allow for a
fast, easy, and reliable dissolution test that provides dissolution data from a 4-vessel
system. The system captures the processes relevant to in vivo dissolution including
disintegration, particle transfer and emptying from the stomach, dissolution in the
stomach and intestinal fluids, and the changes in dissolution rate and solubility
associated with the change in pH across the system. The system is not meant to be a
perfect analogue of each process, but a simplified version that allows for in vitro testing.
Multi-compartment dissolution devices have long existed. However, the design of GIS-2
provides customizability that is not present in other systems and the amount of control
of experimental parameters in the software provide infinite possibilities in designing a
dissolution experiment. Future work in the GIS-2, including work included in this
dissertation, can show the capabilities of the GIS-2 as a formulation evaluation tool.
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Chapter 4.
Preliminary Determination of in
vitro-in vivo correlations (IVIVC) in
the Gastro-Intestinal Simulator-2
(GIS-2)
4.1. Introduction
Oral drug formulations must undergo multiple processes for its active ingredient to
reach the site of action. These processes can vary from person to person and their
interactions between the drug molecule and those processes. In order to determine in
vivo performance, animal and human studies are conducted to directly determine that
performance. However, in order to prevent unnecessary and uninformed in vivo
experiments from commencing, in vitro dissolution tests are a valuable part of the
formulator’s toolkit. Thus, an in vitro device that is informed by the in vivo processes
can be used to predict in vivo performance. Culen et al. states that in order to achieve
an in vitro-in vivo relationship, physiologically relevant dissolution results are
necessary.1 The Gastro-Intestinal Simulator-2 (GIS-2) was designed based on the
physiological processes and conditions of the in vivo physiology.2,3 In order to
determine its applications, in vitro-in vivo correlations (IVIVC) were attempted to be
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determined from in vitro dissolution on the GIS-2 compared to existing in vivo plasma
data from the literature. Ibuprofen is a BCS-II drug and a weakly acidic molecule.
Clinical data has shown that intestinal solution concentrations are the driving force for
absorption rates into the plasma.4,5 Furthermore, dissolution depends on luminal pH,
gastric motility events and gastric emptying rate, in both fed and fasted states.4,5
According to FDA guidance, in vitro-in vivo correlations are a valuable tool in
quantifying drug release into systemic circulation.6 This is especially useful in replacing
a costly in vivo bioequivalence study with a simple, cost-effective in vitro test. IVIVCs
have multiple correlation levels: Level A, B and C. Level-A has the strongest level of
correlation, with a point to point relationship between dissolution rate and plasma
profile. Level B compares parameters associated with each instance, say mean
dissolution time in vitro testing to mean residence time from the in vivo profile. Level C
compares data from a single timepoint of the in vitro data to a value from the in vivo
data. Level A is the only valid correlation for replacing bioequivalence studies as levels
B & C cannot directly predict the entire plasma profile. In order to apply in vivo
relevant dissolution to existing plasma data, an understanding of the pharmacokinetics
is necessary.6 Once ibuprofen reaches systemic circulation, it has been shown to follow
a two-compartment pharmacokinetic model, but one-compartment model has been
shown to be applicable in certain circumstances.4 In some circumstances, where onset
of in vitro dissolution occurs more rapidly than the drug is observed in the plasma in
vivo, time scaling may be applied to the data in order to improve the fit.7-10 Typically
time scaling is applied with the development of a Levy Plot.7 In addition, for
multi-compartment dissolution devices, single vessel dissolution profiles can be
correlated with plasma concentration-time profiles using time scaling with some
success.1
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4.2. Materials and Methods
4.2.1. Materials
All materials were of analytical grade or higher, unless otherwise specified. Acetonitrile
for HPLC analysis was HPLC Grade (Fisher Scientific) and trifluoroacetic acid was
LC/MS-grade (Sigma-Aldrich, St. Louis, MO).
4.2.2. GIS-2 Device & Dissolution Method
The GIS-2 is a computer-controlled, four-vessel dissolution device for testing oral
formulations. The four vessels represent the stomach, duodenum, jejunum, and ileum.
The conditions of the experiment can be adjusted, including initial volumes, stomach
emptying profile, secretion rates, temperature, pH, buffer capacity and ionic strength.
pH was continuously monitored throughout the experiment. The vessels are
flat-bottomed cylindrical glass jacketed vessels. The vessels are mixed using top-down
stirring, controlled by digital motors (Myostat Motion Control Inc., Newmarket, ON
Canada). The stirrers are appropriately sized 3-blade hydrofoils (Manufacturer,
Location). Stirring was maintained at speed, cycling between a lower speed to suspend
most particles, with a one second burst, every sixty seconds to re-suspend any particles
that may have settled to the bottom of the vessel. All fluid transfer was controlled by
Ismatec Reglo ICC peristaltic pumps (Cole-Parmer GmbH, Wertheim, Germany). Pumps
were standardized with water on day of analysis before analysis. Initial conditions can
be found in Table 4.1. The stomach emptied from 300 mL, initially, to 75 mL with
first-order kinetics (t1/2: 30 min). Volume was maintained at 50 mL in the duodenum
and jejunum. The ileum accumulated all excess volume to maintain the first three
vessels. After the stomach reached 75 mL, the experiment continued for one hour, with
secretions only, with the stomach, duodenum, and jejunum volumes held constant.
Formulations were pre-disintegrated in the stomach, by stirring at 120 RPM for 10
minutes, before fluid transfer was initiated. Manual samples were taken at regular
intervals, aliquoting 1.5 mL from each vessel. Aliquots were filtered through a 0.45 um
syringe filter, discarding the first 0.5 mL. Remaining filtrate was diluted as necessary for
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Vessel Initial Volume and
Media
Stir
Speed
(RPM)
Burst
Speed
(RPM)
Secretion Buffer
and Rate
Stomach 300 mL: 250 mL of
2mM SDS 50 mL of
0.01N HCl w/ 2mM
SDS, 100 mM ionic
strength (adjusted
with NaCl)
120 240 2.5 mL/min: 50
mL of 0.01N HCl
w/2mM SDS,100
mM ionic strength
(adjusted with
NaCl)
Duodenum
& Jejunum
50 mL of 50 mM Phos-
phate Buffer pH 6.5,
150 mM ionic strength
(adjusted with NaCl)
175 350 1 mL/min: 100
mM Phosphate
Buffer pH 6.5, 150
mM ionic strength
(adjusted with
NaCl)
Ileum 250 mL of 50 mM
Phosphate Buffer pH
6.5, 150 mM ionic
strength (adjusted
with NaCl)
75 150 NA
Table 4.1: Standard GIS-2 media and stirring conditions for experiments.
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HPLC analysis. Media removed from each vessel was replaced with appropriate
secretion media to maintain volume.
4.2.3. USP-2 Dissolution Method
500 mL of 50 mM Phosphate Buffer pH 6.5 was added to a standard 900 mL USP-2
dissolution vessel and allowed to equilibrate to 37°C. Once equilibrated, the tablets were
introduced to the media. Manual samples were taken at regular intervals, aliquoting 1.5
mL from each vessel. Aliquots were filtered through a 0.45 µm syringe filter, discarding
the first 0.5 mL. Remaining filtrate was diluted as necessary for HPLC analysis. Media
removed from each vessel was replaced with appropriate secretion media to maintain
volume.
4.2.4. HPLC Method
Filtered and diluted samples were analyzed by an isocratic reverse phase HPLC method
(Agilient 1100 Series, Santa Clara, CA) using an Agilent C-18 column (3.5µm x 4.6µm x
150mm). Mobile phase was a 60:40 mix of acetonitrile:water with 0.1% trifluoroacetic
acid. The column was maintained at 40°C with a mobile phase flow rate of
1.0mL/minute. UV detection was performed at 220 nm. A standard curve was prepared
bracketing the sample solutions.
4.2.5. Formulations
Formulations used in the experiment were Motrin IB (McNeil Consumer Healthcare,
Fort Washington, PA) and ibuprofen sodium (Pfizer, Madison, NJ). Two tablets were
introduced to the experiment for a total dose of 400 mg ibuprofen.
4.2.6. Compartmental Approaches to IVIVC
Pharmacokinetic parameters for Wagner-Nelson and Loo-Riegelman deconvolution and
convolution were calculated using the PKSolver add-in for Microsoft Excel.11 These
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parameters are summarized in Table 4.2. Fraction absorbed (Fa) was estimated using
Wagner-Nelson and Loo-Riegelman deconvolution methods performed in Excel using
the parameters from Table 4.1, with the area under the curve (AUC) estimated by the
trapezoid method. Levy plots were generated using interpolated times for increments of
Fa and fraction dissolved (Fd).
Wagner-Nelson Parameters Loo-Riegelman Parameters
Ke (1/hr) 0.63 K10 (1/hr) 0.79
Vd (L) 5.2 K12 (1/hr) 2.79
K21 (1/hr) 3.73
Table 4.2: Summary of PK parameters as determined by PKSolver add-in for Microsoft
Excel
4.2.7. Predictability Evaluation
In order to determine the validity of the correlations generated below, the predictability
was evaluated by calculating the prediction error for the area under the curve (AUC)
and Cmax. The prediction error is calculated by equation 4.1, below:
𝑃𝐸(%) = |𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 − 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑|𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 ∗ 100 (4.1)
All prediction error values calculated are for internal predictability, as both
formulations are used to create the correlation. FDA guidance for internal predictability
requires average absolute prediction error to be less than 10% for both parameters and
no individual formulation can have PE exceed 15%.6
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4.3. Results
4.3.1. Dissolution Data
GIS-2
Ibuprofen formulations were introduced to the stomach of the GIS-2 and dissolution
was observed over a two-hour experiment. The dissolution of ibuprofen from the
Motrin IB formulation is shown in Figure 4.1. Over the course of the same experiment,
pH was continuously monitored in all four dissolution vessels, as shown in Figure 4.2.
Figure 4.1: GIS-2 dissolution profiles for Motrin IB, in each vessel [Stomach (●), Duode-
num (●), Jejunum (●), and Ileum(●)]. Dissolution data for Ileum vessel is plotted on the
secondary y-axis for clarity of the other vessels.
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Figure 4.2: GIS-2 pH Data for Motrin IB, in each vessel [Stomach (–), Duodenum (–),
Jejunum (–), and Ileum(–)].
Figure 4.3 shows the comparison of total dissolution of ibuprofen between the two
formulations, Motrin-IB (ibuprofen) and the ibuprofen sodium tablets in the intestinal
vessels of GIS-2. These data are co-plotted on two y-axes to represent the mass
dissolved and fraction dissolved (Fd) on the left and right, respectively. The Fd from
these data are used in determining the correlations to in vivo data. Ibuprofen sodium
dissolved more quickly and to a greater extent due to the higher solubility of the
sodium salt under low bulk pH conditions. This allowed less solid material to remain in
the stomach and prevented the loss of undissolved material to the system (i.e. filtration
of samples).
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Figure 4.3: Total ibuprofen dissolved in the intestinal vessels of the GIS for the Ibuprofen
Sodium (●) and Motrin IB (●) formulations.
USP-2
Figure 4.4 shows the comparison of total dissolution of ibuprofen between the two
formulations, Motrin-IB (ibuprofen) and the ibuprofen sodium tablets from USP-2
dissolution. These data are co-plotted on two y-axes to represent the mass dissolved
and fraction dissolved (Fd) on the left and right, respectively. The Fd from these data are
used in determining the correlations to in vivo data. Ibuprofen sodium dissolved more
quickly than the Motrin formulation. This is likely due to the faster observed
disintegration time for that formulation as there is a limited solubility difference
between ibuprofen and its sodium salt at pH 6.5.
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Figure 4.4: Total ibuprofen dissolved in the 500 mL USP-2 dissolution for the Ibuprofen
Sodium (●) and Motrin IB (●) formulations.
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4.3.2. Loo-Riegelman
Figure 4.5 shows the results of deconvolution of ibuprofen and ibuprofen sodium
plasma profiles, as determined by Dewland, Reader & Berry and the PK parameters
shown in Table 4.2.12 The results of this deconvolution resulted in a fraction absorbed
exceeding 100% for both formulations. This is likely due to the sourcing of data from
literature and the nature of two-compartment pharmacokinetic modeling. Since the PK
parameters determined from infusion data separate from the oral dosed data used for
deconvolution, it’s likely that error was introduced into the prediction of fraction
absorbed. Additionally, Lockwood, et al. showed that pharmocokinetic parameters for
two-compartment models have high variability within the sample population (shown
by large confidience intervals for each parameter) and inter-study comparisons show
large differences between determined values. This is especially true with both
parameters involving the peripheral compartment, where the amount of drug in the
peripheral compartment must be estimated and poor estimation of those values can
lead to systemic error. This deconvolution is incongruent with expectations for fraction
absorbed. However, for the sake of the exercise of determining an IVIVC for the
dissolution data using a two-compartment model, these deconvoluted data will be used
in place of improving the data with population matched infusion and oral dosed human
subjects.
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Figure 4.5: Deconvolution using the Loo-Riegelman model from plasma profiles of
Ibuprofen Sodium (●) and ibuprofen (●) formulation.12
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Figure 4.6 shows the nonlinear fitting of fraction absorbed in vivo and fraction
dissolved in vitro (GIS-2). A non-linear fit is allowed under FDA guidance and provided
a higher level of correlation than a linear fit.
Figure 4.6: IVIVC plot for fraction absorbed from Loo-Riegelman deconvoluted plasma
profiles of Ibuprofen Sodium (●) and ibuprofen (●) and the fraction dissolved from GIS-2
intestinal dissolution .
Using the correlation shown in Figure 4.6, the dissolution data determined using GIS-2
was used to predict Fa values at each time point. These Fa values were used to predict
plasma profiles for both formulations by Loo-Riegelman convolution. These predicted
plasma profiles are shown in Figures 4.7 & 4.8. The predicted values for Cmax and AUC
of each formulation were compared to the observed values for both parameters. The
validity of the correlation was tested by calculating the prediction error, as shown in
Table 4.3. The correlation met the criteria for both Cmax values and the AUC for the
Motrin formulation, but failed to meet the FDA criteria for the AUC of ibuprofen, so the
correlation was rejected.
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Figure 4.7: Loo-Riegelman predicted plasma profile for the Motrin IB formulation (–)
compared to the observed plasma profile (■) from (Dewland, et al.)12.
Figure 4.8: Loo-Riegelman the predicted plasma profile for the ibuprofen sodium formu-
lation (–) compared to the observed plasma profile (■) from (Dewland, et al.)12.
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Parameter Observed Predicted %Prediction Error
CMax (motrin IB)
(µg/mL)
26.37 29.13 10.4
AUC (motrin IB)
(µg/mL·hr)
121.22 111.89 7.7
CMax (Ibuprofen
Sodium) (µg/mL)
38.04 39.79 4.6
AUC (Ibuprofen
Sodium) (µg/mL·hr)
120.71 164.32 36.0
Table 4.3: Summary of Prediction Error from Loo-Riegelman Correlations and Predic-
tions
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4.3.3. Wagner-Nelson
As described by Bermejo, 2018, though ibuprofen is typically described by a
two-compartment model, a one-compartment model can be used to sufficiently analyze
ibuprofen with a similar level of accuracy. Deconvolution of the same plasma profiles as
in Figure 4.5 is shown below in Figure 4.9.
Figure 4.9: Deconvolution using the Wagner-Nelson model from plasma profiles of
Ibuprofen Sodium (●) and ibuprofen (●) formulation.12
Figure 4.10 shows the linear fit of fraction absorbed in vivo and fraction dissolved in
vitro (GIS-2) with a correlation of R2 = 0.9585.
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Figure 4.10: IVIVC plot for fraction absorbed fromWagner-Nelson deconvoluted plasma
profiles of Ibuprofen Sodium (●) and ibuprofen (●) and the fraction dissolved from GIS-2
intestinal dissolution.
Using the correlation shown in Figure 4.10, the dissolution data determined using GIS-2
was used to predict Fa values at each time point. These Fa values were used to predict
plasma profiles for both formulations by Wagner-Nelson convolution. These predicted
plasma profiles are shown in Figures 4.11 & 4.12. The predicted values for Cmax and
AUC of each formulation were compared to the observed values for both parameters.
The validity of the correlation was tested by calculating the prediction error, as shown
in Table 4.4. The correlation failed to meet the FDA criteria for prediction error for
three of the four predicted parameters, with only the Cmax of the ibuprofen sodium
formulation meeting the criteria and the correlation was rejected.
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Figure 4.11: Wagner-Nelson predicted plasma profile for the Motrin IB formulation (–)
compared to the observed plasma profile (■) from (Dewland, et al.)12.
Figure 4.12: Wagner-Nelson predicted plasma profile for the ibuprofen sodium formula-
tion (–) compared to the observed plasma profile (■) from (Dewland, et al.)12.
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Parameter Observed Predicted %Prediction Error
CMax (motrin IB)
(µg/mL)
26.37 38.49 46.0
AUC (motrin IB)
(µg/mL·hr)
121.22 96.98 20.1
CMax (Ibuprofen
Sodium) (µg/mL)
38.04 41.40 8.8
AUC (Ibuprofen
Sodium) (µg/mL·hr)
120.71 98.0 18.8
Table 4.4: Summary of Prediction Error from Wagner-Nelson Correlations and Predic-
tions
4.3.4. Levy Plot
Neither the Wagner-Nelson model nor the Loo-Riegelman model resulted in
correlations that successfully met FDA requirements. However, both correlations
showed in vivo lag time due to some other physiological or formulation characteristic,9
which can be corrected for using a Levy Plot. The following section used Levy Plots to
attempt to improve upon the correlations from above.
Loo-Riegelman
A levy plot was generated by linear interpolation of the FA and FD data for both
formulations, pairing the times of FA and FD values from 0-100% in increments of 10% .
The levy plot for the Loo-Riegelman FA values (from Figure 4.1) and GIS-2 intestinal
dissolution FD data is shown in Figure 4.13. The two formulations show distinct
individual slopes for their respective paired time points, which is evident by the poor
correlation (R2 = 0.5036). This levy plot was not usable to create a predictions of plasma
concentrations from the FD data and was rejected.
85
Figure 4.13: Levy Plot for time in vivo to specified Fa from Loo-Riegelman deconvolution
of Ibuprofen Sodium (●) and ibuprofen (●) and the time in vitro for fraction dissolved
matched to the in vivo time.
Wagner-Nelson
A levy plot was generated by linear interpolation of the FA and FD data for both
formulations, pairing the times of FA and FD values in increments of 10%. For
Wagner-Nelson one-compartment model, levy plots were generated for both total dose
normalized FDAnd final mass dissolved in the intestinal compartments (Fdiss-inf)
Dose Normalized
The levy plot for the Wager-Nelson FA values (from Figure 4.9) and GIS-2 intestinal
dissolution FD data normalized to the dose is shown in Figure 4.14. The fraction for
each formulation is truncated at 70% and 80% for Motrin IB and ibuprofen sodium
formulations, respectively. This truncation is due to the maximum FD observed during
the experiment when normalizing to the dose. The two formulations similar slopes
with a correlation of R2 = 0.8924. Using this levy plot the plasma profiles can be
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predicted by using the correlation to produce the equivalent time in vivo (TA)
associated to the FD at time in vitro (TD)
Figure 4.14: Levy Plot for time in vivo to specified Fa fromWagner-Nelson deconvolution
of Ibuprofen Sodium (●) and ibuprofen (●) and the time in vitro for fraction dissolved,
normalized to dose, matched to the in vivo time.
Using the Levy Plot, shown in Figure 4.14, the dissolution data determined using GIS-2
was used as Fa values with each time point scaled using the relationship from the Levy
Plot. These Fa values were used to predict plasma profiles for both formulations by
Wagner-Nelson convolution. These predicted plasma profiles are shown in Figures 4.15
& 4.16. The predicted values for Cmax and AUC of each formulation were compared to
the observed values for both parameters. The validity of the correlation was tested by
calculating the prediction error, as shown in Table 4.5. The correlation met the criteria
for both AUC values and the Cmax for the ibuprofen sodium formulation but failed to
meet the FDA criteria for the Cmax of ibuprofen, so the correlation was rejected.
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Figure 4.15: Time-scaled Wagner-Nelson (dose normalized) predicted plasma profile for
theMotrin IB formulation (–) compared to the observed plasma profile (■) from (Dewland,
et al.)12.
Figure 4.16: Time-scaled Wagner-Nelson (dose normalized) predicted plasma profile for
the ibuprofen sodium formulation (–) compared to the observed plasma profile (■) from
(Dewland, et al.)12.
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Parameter Observed Predicted %Prediction Error
CMax (motrin IB)
(µg/mL)
26.37 34.23 29.8
AUC (motrin IB)
(µg/mL·hr)
121.22 127.69 5.3
CMax (Ibuprofen
Sodium) (µg/mL)
38.04 42.78 12.5
AUC (Ibuprofen
Sodium) (µg/mL·hr)
120.71 126.18 4.5
Table 4.5: Summary of Prediction Error from Time-scaled Wagner-Nelson (dose normal-
ized) Correlations and Predictions
Final Amount Dissolved Normalized
The levy plot for the Wager-Nelson FA values (from Figure 4.9) and GIS-2 intestinal
dissolution FD data normalized to the final mass dissolved (FDiss-inf) is shown in Figure
4.17. The two formulations similar slopes with a correlation of R2 = 0.9484. Using this
levy plot the plasma profiles can be predicted by using the correlation to produce the
equivalent time in vivo (TA ) associated to the FDAt time in vitro (TD ).
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Figure 4.17: Levy Plot for time in vivo to specified Fa fromWagner-Nelson deconvolution
of Ibuprofen Sodium (●) and ibuprofen (●) and the time in vitro for fraction dissolved,
normalized to final mass dissolved, matched to the in vivo time.
Using the Levy Plot, shown in Figure 4.17, the process from the previous section is
repeated to predict plasma profiles for both formulations. These predicted plasma
profiles are shown in Figures 4.18 & 4.19. The predicted values for Cmax and AUC of
each formulation were compared to the observed values for both parameters. The
validity of the correlation was tested by calculating the prediction error, as shown in
Table 4.6. The correlation met the criteria for both AUC values and but failed to meet
the FDA criteria for both Cmax values, so the correlation was rejected.
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Figure 4.18: Time-scaled Wagner-Nelson (normalized to final mass dissolved) predicted
plasma profile for the Motrin IB formulation (–) compared to the observed plasma profile
(■) from (Dewland, et al.)12.
Figure 4.19: Time-scaled Wagner-Nelson (normalized to final mass dissolved) predicted
plasma profile for the ibuprofen sodium formulation (–) compared to the observed plasma
profile (■) from (Dewland, et al.)12.
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Parameter Observed Predicted %Prediction Error
CMax (motrin IB)
(µg/mL)
26.37 19.64 26.8
AUC (motrin IB)
(µg/mL·hr)
121.22 120.24 0.8
CMax (Ibuprofen
Sodium) (µg/mL)
38.04 35.11 16.5
AUC (Ibuprofen
Sodium) (µg/mL·hr)
120.71 121.08 0.1
Table 4.6: Summary of Prediction Error from Time-scaled Wagner-Nelson (normalized
to final mass dissolved) Correlations and Predictions
USP-2 (Wagner-Nelson)
A levy plot was generated by linear interpolation of the FA and FD data for both
formulations, pairing the times of FA and FD values from 0-100% in increments of 10%.
The levy plot for the Wagner-Nelson FA values (from Figure 4.1) and dissolution in the
USP-2 dissolution vessel FD data is shown in Figure 4.13. The two formulations show
distinct individual slopes for their respective paired time points, which is evident by the
poor correlation (R¬2 = 0.6841). This levy plot was not usable to create a predictions of
plasma concentrations from the FD data and was rejected.
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Figure 4.20: IVIVC plot for fraction absorbed fromWagner-Nelson deconvoluted plasma
profiles of Ibuprofen Sodium (●) and ibuprofen (●) and the fraction dissolved from USP-2
dissolution.
4.4. Discussion
When designing an in vitro device, utilizing the knowledge of the in vivo processes that
act on an oral formulation can be an improvement over conventional dissolution.
Multi-compartment dissolution devices have demonstrated good correlation with in
vivo data.1 The Gastro-Intestinal Simulator 2 (GIS-2) is a system that applies those
processes to produce in vivo¬ based dissolution conditions. In order to test the
capability of the GIS-2 to be in vivo-like, IVIVCs were developed and evaluated, using
two different compartment models.
Dissolution data for USP-2 and GIS-2 dissolution shows varied kinetics and extent for
dissolution (Figures 4.1 & 4.3). Using these dissolution data and the fraction absorbed
from in vivo plasma data for similar formulations the correlations were generated, as in
Figure 4.10. Using these correlations, plasma profiles were predicted for each
correlation. Neither model met the requirements for IVIVC per FDA guidance without
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time scaling. The Loo-Riegelman correlation had more parameters meet FDA
requirements with three of the four parameters meeting requirements. However, the
shape of the plasma profile has an odd jut at the three hour mark, likely due to the
difficulty in predicting peripheral drug concentration in the Loo-Riegelman method and
the large confidence interval related to PK parameters in the two-compartment model
of ibuprofen. Moreover, both correlations show in vivo lag, where the correlation was
shifted right on the x-axis instead of intersecting near the origin. Therefore, time
scaling was a necessary step to attempt to improve the correlation.
With the introduction of time scaling, by use of a Levy Plot, the two formulations were
shown to have separate slopes and the low-quality correlation for the Loo-Riegelman
method. This likely related to the difficulties in estimating a two-compartment model
without infusion data and oral plasma data from the same subject group in order to
accurately estimate the pharmacokinetic parameters. This is exacerbated by the
inclusion of time-scaling, which relies on fraction absorbed values to remain within the
bounds of 0-100%. When the same time scaling procedure was applied to the fraction
absorbed data from Wagner-Nelson deconvolution, linearity was found. When using
this time scaling to predict plasma concentrations, the lowest average predicted error
across all models for AUC were observed, but failed to predict the Cmax within the
FDA criterion. Therefore, the correlations were rejected. Although the Cmax failed to
meet requirements, this may not be directly the fault of the correlation method. Due to
the interpolation necessary for the time scaling of the Levy Plot, insufficient data may
have been gathered in vitro to allow for full coverage of the early absorption phase
leading up to the Cmax resulting in the predicted plasma curves to be plateau shaped or
with depressed peaks (Figures 4.18 & 4.19). In comparison to conventional dissolution,
(USP-2) the in vivo-inspired GIS-2 was far more successful at correlating to in vivo data.
The Levy Plot generated from USP-2 dissolution data had similar issues as the
Loo-Riegelman Levy plot for GIS-2, where the formulations had divergent slopes.
However, this does not take away from the usefulness of USP-2 dissolution, just under
these circumstances the GIS-2 in its current state has some advantages.
With the lack of evidence of a correlation between GIS-2 dissolution and in vivo plasma
data, some improvements could be made to the studies described. First, the
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formulations used have identical absorption kinetics since they are the same parent
drug molecule. However, the formulations are the free acid and sodium salt, which have
different dissolution behavior due to differences in their pH-dependent solubilities.
Thus, different formulations of the same drug molecule should be tested to improve the
quality of correlations.
Next, the PK data and parameters for the models were based on separate sources of data
from literature. Ideally, the PK parameters and the plasma profiles being correlated with
from oral dosing of the drug would be generated from the same subjects in order to
reduce subject variability. As shown in Lockwood, et al., for ibuprofen the confidence
interval for the PK parameters for both inter-study and intra-study are quite wide.13
Thus, performing PK studies may be necessary to truly have correlative dissolution.
Third, the GIS-2 dissolution method is far from optimized. These data were generated
as proof of concept dissolution studies and were then applied to the in vivo data
without any optimization to the method. Areas of improvement for the method include:
1) using more in vivo relevant gastric emptying times; 2) increasing the number of
sampling timepoints in the early stages of the experiment to improve resolution of the
dissolution data; 3) reducing the pre-disintegration time; 4) using biorelevant buffers
(bicarbonate or equivalent phosphate buffer) in the duodenum and jejunum vessels; and
5) using titration to maintain duodenal (and jejunal) bulk pH within a relevant range
over the course of the experiment. With these method improvements in mind, future
dissolution experiments in the GIS-2 may provide better correlations to in vivo data.
Last, when considering ibuprofen, a BCS IIa compound, the processes that limit
absorption are: disintegration of the dosage form, drug particle emptying/transit from
the stomach into the duodenum and jejunum, and dissolution in the intestinal fluid, as
limited dissolution will occur in the acidic conditions of the stomach. However, a
weakly basic drug with high permeability (BCS IIb) could benefit from study in the
GIS-2, as the pH change from gastric conditions into the intestine; thus, allowing for
capture of the supersaturation and precipitation behavior that occurs in vivo for that
class of molecules. The GIS-2 is tailored for low solubility drugs in its current state.
However, when supersaturation and precipitation occur, for weakly basic drugs, an
absorption process for the GIS-2 may be necessary to capture differences in
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supersaturation and precipitation behavior as supersaturation may be maintained for
longer when absorption is allowed to occur at supersaturated drug concentrations. The
above discussed method improvements are one of the benefits of the GIS-2 system, the
simplicity and modularity of its design allows for the dissolution test to be tailored to
the needs of the API and formulation(s) being tested.
4.5. Conclusions
The capability of a dissolution device that provides discriminative and in vivo
correlative dissolution could be a powerful tool in development of oral dosage forms.
The GIS-2 was designed to incorporate the processes in vivo that affect drug dissolution
and absorption. Although the results of this work lack evidence of correlative
dissolution, the results do provide a promising framework for the future correlative
dissolution. The system has the capability for further optimization, which could allow
for improved correlations, including media selection, gastric emptying, and introduction
an absorption compartment. The study also lacked quality or distinct data for each
formulation. Rather, in vivo data was used from literature for the purpose of this study
and was not produced directly from the formulations used in the GIS-2 dissolution
experiments. Additionally, PK parameters were derived from IV infusion data separate
from the source of the oral dosage PK profiles. Despite the difficulties described above,
the GIS-2 has the potential to be used as a benchtop evaluator of formulations and with
further refinement should be capable of predicting their behavior in vivo.
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Chapter 5.
Formulation Evaluation –
Comparison of Conventional Tests to
Gastrointestinal Simulator-2
5.1. Introduction
Regardless of route of administration, optimization of a drug formulation is crucial
across all steps of the development process. Fonner, Buck, and Banker, some of the first
applications of mathematical optimization techniques to pharmaceutical systems, state
that determining the effects of controllable variables on the response variable
accurately requires a statistically well designed and extensive series of experiments.
Further complicating matters is that certain design objectives are competing, such as
tablet friability and disintegration time, or tablet hardness and drug dissolution rate.1
This means that most formulation behaviors are constrained variables, that is, that
variable cannot be optimized for ad infinitum without consideration towards the effect
on another. Although the system for drug dissolution of an oral formulation is
governed by observable laws, the system is so complicated that an empirical approach
is necessary, as is true for most industrial systems.2,3 This optimization involves a set of
designed experiments and determining a mathematical model that describes the effects
of each process variable on the response variable in order to determine the optimal
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levels for each process variable.1,4,5 On such statistical design for experiments is the
Placket-Burman design.6 Plackett-Burman is screening experiments designed to use the
minimum amount of experiments to determine the main effects of interest. The design
is typically used for screening as multi-factor interactions are assumed to be negligible
and the results are confounded by any multi-factor interactions. Conventional in vitro
evaluation techniques for the optimization of oral formulations are: disintegration,
tablet hardness, dissolution, friability.1,4,5 Though separately these experiments are
important for determining manufacturing variability, they lack in vivo relevance that
another test may have. However, in order to test the viability of the GIS-2 system as a
potential system for evaluating formulations, a comparison between it and
conventional tests is necessary. Therefore, the goal of this study is to determine the
sensitivity of GIS-2 dissolution to a set of process variables compared to the USP
disintegration test and modified non-compendial USP-2 dissolution, with the end goal
of GIS-2 determining what factors are important to a particular drug. For this study,
ibuprofen will be used along with excipients typically found in on-the-market
ibuprofen oral formulations.
5.2. Materials and Methods
5.2.1. Materials
All materials were of analytical grade or higher, unless otherwise specified. Acetonitrile
for HPLC analysis was HPLC Grade (Fisher Scientific) and trifluoroacetic acid was
LC/MS-grade (Sigma-Aldrich, St. Louis, MO).
5.2.2. Preparation of Formulations
Pure ibuprofen was sieved through a set of sieves and the solids from a portion of sieves
was collected. The sieved ibuprofen was used in all formulations. Formulations were
designed based on a Plackett-Burman design with seven factors and eight formulations.
The Plackett-Burman array is shown in Table 1 of Appendix 1. Note that formulation #9
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is a repeat of formulation #5 for the sake of determining experimental error.
Formulations were made as 25 g batches, as described in Table 2 of Appendix 1. All
excipients, except magnesium stearate, and ibuprofen were weighed and screened
through an 18-mesh sieve. The sieved components were mixed in a V-blender for 5
minutes. After V-blending, 5g of the mix was added to the weighed magnesium stearate
and screened through the 18-mesh sieve twice. This sieve mixture was re-added to the
V-blender and mixed for 2 minutes. Mixture was transferred to a plastic bag for storage
before compression. Into a 9.5mm diameter circular convex tablet punch and die, 220
mg of the formulation mixture was added. Compression force was varied per
compressed tablet until the desired solid fraction was achieved. Procedure was repeated
until twenty tablets were produced for each formulation.
5.2.3. Disintegration Method
Disintegration was performed in a USP disintegration apparatus. The procedure was
based on USP general chapter <701>.7 Into each tube of the basket, one tablet was
added. The basket was allowed to cycle up and down in approximately 750 mL of water
for 10 minutes at 30 cycles per minute. Time was recorded for each individual tablet
when it had been determined to full disintegrated. Average and standard error for each
formulation was calculated and reported.
5.2.4. USP-2 Dissolution Method
Dissolution procedure was modified from the USP general chapter <711> for
dissolution.8 500 mL of 50 mM phosphate buffer pH 6.5, with ionic strength adjusted to
150 mM with sodium chloride, was added to a standard 900 mL USP-2 dissolution vessel
and allowed to equilibrate to 37C. Once equilibrated, the tablets were introduced to the
media. Manual samples were taken at regular intervals, aliquoting 1.5 mL from each
vessel. Aliquots were filtered through a 0.45 um syringe filter, discarding the first 0.5
mL. Remaining filtrate was assayed by HPLC. Media removed from each vessel was
replaced with appropriate secretion media to maintain volume. Procedure was repeated
in triplicate for each formulation.
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5.2.5. GIS-2 Device & Dissolution Method
Device
The GIS-2 is a computer-controlled, four-vessel dissolution device for testing oral
formulations. The four vessels represent the stomach, duodenum, jejunum, and ileum.
The conditions of the experiment can be adjusted, including initial volumes, stomach
emptying profile, secretion rates, temperature, pH, buffer capacity and ionic strength.
pH is continuously monitored throughout the experiment. The vessels are
flat-bottomed cylindrical glass jacketed vessels. The vessels are mixed using top-down
stirring, controlled by digital motors (Myostat Motion Control Inc., Newmarket, ON
Canada). The stirrers use appropriately sized 3-blade hydrofoils (MXD, Louisville, KY).
Method
The device was controlled by software developed in Labview (National Instruments,
Austin, TX). Stirring was maintained at speed, cycling between a lower speed to
suspend most particles, with a one second burst, every sixty seconds to re-suspend any
particles that may have settled to the bottom of the vessel. All fluid transfer was
controlled by Ismatec Reglo ICC peristaltic pumps (Cole-Parmer GmbH, Wertheim,
Germany). Pumps were standardized with water on day of analysis before analysis.
Initial conditions can be found in Table 5.1. The stomach emptied from 300 mL, initially,
to 75 mL with first-order kinetics (t1/2: 30 min). Volume was maintained at 50 mL in
the duodenum and jejunum. The ileum accumulated all excess volume to maintain the
first three vessels. After the stomach reached 75 mL, the experiment continued for one
hour, with secretions only, with the stomach, duodenum, and jejunum volumes held
constant. Formulations were pre-disintegrated in the stomach, by stirring at 120 RPM
for 10 minutes, before fluid transfer was initiated. Manual samples were taken at
regular intervals, aliquoting 1.5 mL from each vessel. Aliquots were filtered through a
0.45 um syringe filter, discarding the first 0.5 mL. Remaining filtrate was assayed by
HPLC. Media removed from each vessel was replaced with appropriate secretion media
to maintain volume.
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Vessel Initial Volume and
Media
Stir
Speed
(RPM)
Burst
Speed
(RPM)
Secretion Buffer
and Rate
Stomach 300 mL: 250 mL of
2mM SDS 50 mL of
0.01N HCl w/ 2mM
SDS, 100 mM ionic
strength (adjusted
with NaCl)
120 240 2.5 mL/min: 50
mL of 0.01N HCl
w/2mM SDS,100
mM ionic strength
(adjusted with
NaCl)
Duodenum
& Jejunum
50 mL of 50 mM Phos-
phate Buffer pH 6.5,
150 mM ionic strength
(adjusted with NaCl)
175 350 1 mL/min: 100
mM Phosphate
Buffer pH 6.5, 150
mM ionic strength
(adjusted with
NaCl)
Ileum 250 mL of 50 mM
Phosphate Buffer pH
6.5, 150 mM ionic
strength (adjusted
with NaCl)
75 150 NA
Table 5.1: Standard GIS-2 media and stirring conditions for experiments.
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HPLC Method
Filtered and diluted samples were analyzed by an isocratic reverse phase HPLC method
(Agilient 1100 Series, Santa Clara, CA) using an Agilent C-18 column (3.5µm x 4.6µm x
150mm). Mobile phase was a 60:40 mix of acetonitrile:water with 0.1% trifluoroacetic
acid. The column was maintained at 40°C with a mobile phase flow rate of
1.0mL/minute. UV detection was performed at 220 nm. A standard curve was prepared
bracketing the sample solutions.
Statistical Analysis
Statistical analysis was performed on the results from each analysis in order to
determine the effects of each formulation factor on the performance of the formulations.
Using the FrF2 package in R, a part of the DoE.base package for analyzing the design of
experiments.9,10 Statistical significance was determined by a two-sided t-test.
5.3. Results
5.3.1. Disintegration Results
Results from disintegration testing are shown in Table 5.2. The effects of each
formulation factor are shown in Figure 5.1 with the effects and p-values shown in Table
5.3. Copovidone level was the only statistically significant factor in disintegration time,
with increasing copovidone increasing disintegration time. All other factors did not
show statistical significance.
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Formulation Average Disintegra-
tion Time (sec)
Standard Error
(sec)
1 95.0 13.7
2 31.0 2.5
3 311.4 16.9
4 155.6 13.1
5 241.3 13.3
6 110.7 4.6
7 551.9 0.7
8 17.6 5.3
9 253.1 23.9
Table 5.2: Summary of results from disintegration testing. The average disintegration
time and standard error are shown for all formulations
Figure 5.1: Main Effects for each factor for total disintegration time. p < 0.05 = *
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Table 5.3: Summary of Main Effects values for Disintegration Time and their associated
p-value
5.3.2. USP-2 Results
USP-2 dissolution showed some formulation to formulation discrimination, with the
possibility of forming a rank order of the performance of the formulations. Figure 5.2
shows the mass dissolved over time for the nine formulations. However, when
determining effects of the individual factors, none of the formulations showed a
statistically significant effect on dissolution time to 50% of final amount dissolved. The
effect plots for the formulation factors is shown in Figure 5.3.
Figure 5.2: Mass dissolved over time plot of the Plackett-Burman array of formulations
in the USP-2 dissolution experiments.
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Figure 5.3: Main effect plots for each factor for time to 50% of final amount dissolved.
Table 5.4: Summary of Main Effects values for time to 50% in the USP-2 dissolution and
their associated p-value
5.3.3. GIS-2 Dissolution
GIS-2 showed some discrimination between formulations, as shown in Figure 5.4. With
the duplicate formulations (5 & 9) show the greatest dissolution after 90 minutes and
similar profiles of the course of the experiment. By contrast, formulation 2 had less
extent of dissolution. The remaining formulations fell between those two sets of
formulations. When examining the effects of the formulation factors, copovidone levels
and croscarmellose sodium levels had statistically significant effects on dissolution
performance in the GIS-2 device, as shown in Figure 5.5. Dissolution performance was
examined for time to 80% of final mass dissolved.
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Figure 5.4: Mass dissolved over time plot of the Plackett-Burman array of formulations
in the intestinal vessel of the GIS-2
Figure 5.5: Main Effects for each factor for time to 80% of final amount dissolved in the
intestinal vessels of the GIS-2. p < 0.05 = *
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Table 5.5: Summary of Main Effects values for time to 80% in the intestinal vessels of
GIS-2 and their associated p-value
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5.4. Discussion
Three techniques for evaluating formulations were examined using a Plackett-Burman
array. When determining significant effects USP-2 Dissolution showed no significant
effects, though two effects did show high magnitude of effect. This is due to high
experimental variability determined when comparing the duplicated formulation (5 &
9). The USP disintegration test determined the copovidone level had a significant effect
on disintegration time. This is not unexpected, as copovidone is a tablet binder.
Therefore, increasing copovidone level, would increase the time to disintegration. The
GIS-2 test showed the most statistically significant factors. Copovidone was again
shown to be a statistically significant effect, while croscarmellose sodium was also
statistically significant. This result was also expected as croscarmellose sodium is a
disintegrant. Thus, increasing croscarmellose sodium decreases disintegration time for
the tablet and allows undissolved drug particles to reach the duodenum compartment to
dissolve more quickly than at when croscarmellose sodium is at a lower level. It is
surprising that this was not shown to be statistically significant in the disintegration
test. This also shows a potential main mechanism for ibuprofen dissolution in GIS-2.
Ibuprofen dissolution is driven mostly by tablet disintegration stomach emptying. This
is likely why most formulations had similarities in time to 80% dissolved. Since GIS-2
was designed to have in vivo-like dissolution conditions, the observations in effects on
dissolution performance are most likely to transfer over to in vivo performance of drug
formulations.
5.5. Conclusions
GIS-2 was shown to better discern between effects that cause changes in dissolution
behavior. However, these studies were designed for semi-optimized formulations.
Further studies in formulation optimization could be performed in order to determine
further optimization. By widening the range of levels for the factors, more significant
effects may become apparent. Also, due to the nature of Plackett-Burman design, the
interactions between formulation effects were not examined. A design of experiments
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that examines secondary interactions between effects but could be examined with
additional experiments to determine if the GIS-2 is able to detect any secondary effects.
Lastly, since ibuprofen is a BCS IIa drug, its solubility is high in neutral pH conditions,
so disintegration and gastric emptying drive intestinal dissolution. For other
compounds, like BCS class IIb drugs, the processes acting upon the drug molecule are
more complex, including supersaturation in the intestinal compartments. These
additional processes may be more sensitive to formulation changes and could be an area
of study for formulation optimizations in the GIS-2 device.
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Chapter 6.
Conclusions and Future Directions
The goal of this thesis was to develop a new dissolution device that is mechanistically
designed and encapsulates the in vivo processes and conditions and oral dosage form
experiences. The system is based off of the GIS-1, a three-vessel device previously used
for evaluating in vivo performance. The GIS-2 is a four-vessel device, with improved
stirring conditions, gastric emptying profiles based on in vivo emptying kinetics,
titration to allow for use of lower buffer capacity media and empirically determined
hydrodynamics that can be used for dissolution predictions in the GIS-2 device. The
device is designed for modularity with vessels that can be swapped out for other types
of vessels, which allows for user-customizability to match the needs of the drug
molecule and its formulation. With a well-characterized, validated dissolution device in
place, the system can be used for many applications. Based on existing in vitro data
from literature for two ibuprofen formulations, in vitro data was used to attempt to
form a correlation between the data. This was performed in order to determine if the in
vitro-in vivo relevance that is claimed for GIS-2, and systems like GIS-2, was applicable.
No correlations were determined that meet the requirements of the FDA guidance for
Level A correlations. However, the exercise in developing these correlations showed
promise for method development that could lead to improved correlations.
Additionally, correlations were attempted between two different forms of the active
drug molecule, the free acid and a sodium salt. Though they had different plasma
profiles, their dissolution kinetics differed. Population averages were used to determine
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pharmacokinetic parameters, which has been shown to have large confidence intervals
and lead to issues in developing correlations. Also, the sample groups for the PK
parameters and the plasma data for the two formulations were separate sample groups.
Despite all of these challenges, GIS-2 shows promise in its ability to determine in
vivo-in vitro correlations and with improved data inputs could reliably generate
valuable data. Formulations were evaluated under a Plackett-Burman design, by
disintegration, USP-2 dissolution and GIS-2 dissolution in order to determine what
formulation variables affect performance, with the expectation that improved
performance in these in vitro tests can be related to in vivo performance. Since GIS-2
was designed to have in vivo-like dissolution conditions, any observed effects on
dissolution performance are most likely to transfer over to in vivo performance of drug
formulations. The GIS-2 test showed the most statistically significant factors compared
to the other two testing methods. However, these studies were designed for
semi-optimized formulations, by constraining the excipient levels to typical levels used
in manufacturing. Further studies in formulation optimization could be performed in
order to determine further optimization of the formulation. By widening the range of
levels for the factors, more significant effects may become apparent. Also, due to the
nature of Plackett-Burman design, the interactions between formulation effects were
not examined. Further studies in the GIS-2 device could also be designed based on the
experiments performed herein. For all BCS II-IV drugs, the GIS-2 can be modified in
order to meet the needs of the drug molecule. Due to the modular design, an absorption
compartment could be installed to assist in sustaining supersaturation. This is true for
weakly basic drugs, which decrease in solubility as it progresses through the system,
but may also apply to co-crystals, salts and amorphic drug forms. Additionally, the
stomach pH can be modified to mimic drug-drug interactions caused by acid reducing
agents and proton pump inhibitors, which typically affect weakly basic drugs. The
GIS-2 system is an excellent and exciting basis for exploring the oral formulation space.
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Appendix A.
Operating Procedure for GIS-2
Software
Materials and Equipment Preparation
1. Buffer/Solutions
a) Buffer preparation will vary depending on the experiment and
drug/formulation being tested.
b) Example solutions include 0.01N HCl solution with 2mM sodium dodecyl
sulfate and 50 mM phosphate buffer at pH 6.5
2. General Set-up
a) Confirm hydrofoils and other parts are all visibly clean
b) Turn on the water bath such that media temperatures are 37°C. This may
require setting the water bath temperature slightly higher than 37C.
c) Gather materials needed for experiment
d) Check Tubing prior to each experiment
i. Tubing should be replaced when it appears to be permanently crinkled,
very flat or deformed. Visual and physical inspection should be used.
Ideally all tubing should be replaced at the same time. A log of
replacement of GIS 2 tubing should be kept.
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ii. New tubing should be conditions for at least 10 minutes by flowing
water
e) Set up pumping system
i. Attach labeled tubing to tubing clamps following guide on the tubing
for proper placement.
ii. Insert tubing clamps into their appropriate labelled locations, based on
the locations described in the software
f) Calibrate pH meter according to the user manual and on-screen directions
Set up of GIS 2 software and equipment prior to experiment start
1. General information
a) GIS software icon is located on the desktop
b) Software is periodically updated. Always use the most recently updated
version
c) The following instructions will discuss actions required for each screen
2. Screen One: Set Experimental Parameters and Initialize Equipment/Sensors
a) Choose one of the options in the “Choose a Method for the Gastric
emptying Phase” drop down menu. This list may not be all inclusive
b) Choose one of the options in the “Choose the Post-Emptying Phase Action”.
This list may not be all inclusive
i. End GIS-1 after Gastric Emptying Phase
ii. Keep STIRRERS ON (Pumps OFF; Main & Burst stir speeds)
iii. MAINTAIN the S, D, & J volumes w/Stirring (Tx1 = S secretion; Tx2 = S
+ D secretions; Main & Burst Stirring)
A. This feature allows the stomach, duodenum & jejunum volumes to
be maintained at your choice of volume
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B. The slider directly below allows the user to set up an automatic
shut off time after the post-emptying phase has begun
c) Adjust the parameters as needed in “Volume and Rate Parameters”, “Stirring
Speeds” and “Stirring Timing”
i. Values are preset, however may be changed
ii. Stomach volume calculated via the GIS I software as the experiment
run progresses based on gastric emptying rate chosen
A. When the software calculates that the stomach is at final volume
set, the experiment will stop.
B. Choosing a smaller final stomach volume will assure experiment
completion in the event actual and computer generated stomach
volumes are not the same.
iii. Pump rotation and timing parameters may also be changed although
this is not advisable.
d) Saving experimental data (upper right corner)
i. Input desired data file name; a personal data file folder can be created
ii. Input user name
iii. Comments may be included; these will be retained in the output excel
file after experiment is complete (this file also contains transfer rates,
pHs of all probes„ calibration factors used, and initialized parameters)
e) VersaStar Current pH/temp and temperature configuration
i. This section shows configuration and current values for the pH meter.
Under each channel, this section shows the current pH, temperature
and whether a temperature probe is present
f) “Submit Parameters + Initialize Hardware”
i. Once all parameters have been set, click the oval S+I button
ii. Parameters will be submitted and saved in the end data file.
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iii. Once this button is clicked, the green squares above tabs 2 and 3 will
turn green, allowing user to proceed to “Prime/Purge” and/or
“Calibration”
3. Screen Two: Purge or Prime Pump Lines: Pre and Post-Gastric Emptying
a) Pump prime/purge parameters
b) Default values have been chosen to assure adequate time for priming and
purging, however speed and duration may be set for each individual pump.
c) The rpm values should be set as follows; time should be set to 600 seconds
for all pumps to allow adequate tubing conditioning
i. Stomach – 45 rpm
ii. Transfer1 (S-D) –90 rpm
iii. Duodenum – 45 rpm
iv. Transfer2 (D-J) – 90 rpm
v. Jejunum-45 rpm
vi. Transfer3 (J-I)-90 rpm
d) Confirm rotation settings are correct
Table A.1: GIS2A Pump Rotation Directions
i.
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Table A.2: GIS2B Pump Rotation Directions
ii.
e) Rotation of the pump (clockwise and counterclockwise) may be changed but
do so with caution.
i. Before purging/priming after changing flow direction, ensure tubing is
set up to accommodate this direction change
f) Individual confirm buttons for each pump allow testing of one or more
pumps.
g) Once speed and duration are set and confirm buttons chosen, start the
prime/purge cycle by clicking the toggle switch.
h) Repeat as needed
i) Dynamic Status of pumps
i. Slider bars show the status of prime/purge for each pump
j) E-Stop Pumps
i. Click E-stop button on the upper right side of the screen if pumps must
be stopped before prime/purge cycle is complete
k) Set up for prime/purge
i. Fill beakers with deionized water and insert inlet tubing into water
ii. Set up empty beakers at outlet tubing to collect water
iii. Prime/purge the pumps as described
iv. Once pumps are primed/purged move to “Calibrate Pumps” tab
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4. Screen Three: Pump Calibration Factor Determination
a) Pump calibration parameters
i. Default values have been chosen to assure adequate time for calibration,
however speed and duration may be set for each individual pump.
ii. The rpm values should be set as follows; time is 180 seconds for all
pumps
A. Stomach – 10 rpm
B. Transfer1 (S-D) – 50 rpm
C. Duodenum – 10 rpm
D. Transfer2 (D-J) – 50 rpm
E. Jejunum-10 rpm
F. Transfer3 (J-I) – 50 rpm
iii. Rotation of the pumps may be changed but do so with caution
iv. Individual confirm buttons for each pump allow testing of one or more
pumps
v. Once speed and duration are set and confirm buttons chosen, start the
calibration cycle by clicking the “Start Calibration Cycle” toggle switch.
b) Dynamic Status of pumps
i. Slider bars show the status of calibration for each pump
c) E-Stop Pumps
i. Click E-stop button on the upper right side of the screen if pumps must
be stopped before calibration cycle is complete
d) Calibration factors determination
i. Gather six plastic Erlenmeyer flasks which have been labelled and
(empty) tare weight determined.
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ii. Remove glass beakers from outlet tubing and replace with Erlenmeyer
flasks.
iii. After the first calibration cycle is complete, enter the weight of the
empty plastic volumetric flask for each respective pump under the left
“Tare Weight” column
iv. Tab to the “Gross Weight” column
v. Enter the gross weight for each Erlenmeyer flask
vi. This table can be printed and should be used for recording gross and
tare weights, calibration factors and percent difference for each run.
Table A.3: Table for recording pump calibration weights
vii. When the difference of Calibration Factors between runs is within 95 to
105 percent for an individual pump, the pump is considered calibrated
and does not need to be re-calibrated with other pumps not within the
acceptable range.
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viii. Once the percent difference for all pumps is within the appropriate
range, hit “Submit Cal factors” button and proceed to next tab.
5. Screen Four: Gastric Emptying Phase
a) Warm up Stir On/Off-used to turn on stirrers prior to experiment
i. To more quickly heat solutions in vessels
ii. To assure nothing is impeding the rotation of the stirrers prior to the
experiment
b) Dose Drug
i. Optional button which may be pressed prior to dosing drug
c) Start Pumps
i. Dose drug into the stomach beaker
ii. Press “Start pumps” button to begin an experiment
A. If desired, stirrers will run in cycles with intermittent high speed
burst until user ends experiment or pauses
B. Pumps will begin their programmed experimental cycles
d) Pause On/Off & Stop Run early
i. Pause – briefly stops the stirrers and pumps for a user defined amount
of time. Stopwatch tracks the length of a pause
ii. Stop Run Early – ends designated gastric emptying phase and offers
user option to move onto post-emptying phase (Tab 5) or complete end
of experiment and exit out of software
e) Information Screens- screens on this page provide additional information
i. Stirring speeds and cycles-show time to next stirring burst
ii. pH and temperature-shows pH and temperature for each pH probe used
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iii. Pump flow rates and speed” pH and temperatures-flow rates of each
pump are shown. Next to this area is the computer calculated stomach
volume
iv. Stomach, duodenum and jejunum Values
f) Procedure for Starting an Experimental Run
i. Remove calibration beakers and other non-essential materials and
equipment.
ii. Assure all materials are prepared for sampling. Method of sampling and
analysis will vary depending on the experiment.
iii. Insert pH probes and temperature sensors into their respective beakers.
pH probes must be calibrated before each experiment.
iv. Confirm that pH of the solutions in each vessel are within the desired
range. Adjust pH if needed.
v. Place tubing in appropriate containers. Stomach, duodenum and
jejunum inlet tubing should be placed in the appropriate secretion
bottles and transfer tubing should be set up in between vessels. Tubing
should be placed above the hydrofoils.
vi. Press “Dose Drug” button and add dosage form (optional)
vii. Press Start Pump” to begin experimental run
g) Procedure for ending an experimental run
i. Click the red “Stop Run Early” button” if stopping before the end of the
run. Button will turn green once it is pressed
ii. Wait for all cycles (stirrers and pumps) to stop and various text boxes to
appear before proceeding.
iii. If maintain feature was chosen at initialization screen, press “Stop Run
Early” button when stomach volume is at desired maintain volume (for
example 50 mLs). GIS Software will pause briefly before moving on to
tab 5 and “Post Emptying Data Phase” will begin.
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6. Screen Five: Post Emptying Data Phase
a) Post Emptying Phase
i. Chosen post emptying phase is shown in upper left corner of screen
ii. Maintain method will run until the end time specified on the first page
(slider bar)
iii. Run may be stopped early using “Stop Early” button (similar to screen
4: Gastric emptying phase) to end the run at a user specified time.
iv. Information screens similar to that in the gastric emptying phase
provide additional information
v. Once run is ended, pop up information screens will inform user. Final
pop up screen will allow user to return to prime/purge tab for tubing
clean up.
vi. Analysis of stomach, duodenum, jejunum, ileum solutions as well as
tubing and dosage form container may be desired.
vii. Vessel washes may be completed to determine where remaining
undissolved drug is located
A. Rinse the walls of the vessel with a solvent in which the drug is
soluble (eg acetonitrile or methanol)
B. Transfer the contents of the vessel into an appropriately sized
volumetric flask based on initial dose, experience with the
experiment, etc.
C. Rinse any remaining particles from the vessel into the volumetric
flask
D. QS the volumetric flask with buffer or other fluid as needed
E. Remaining particles could be excipients which may not completely
dissolve
F. Filter the final solution before analysis
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G. Perform further dilutions if needed
viii. Tubing Washes
A. Place tubing outlet directly into a volumetric flask.
B. Add appropriate solvent to beaker and place tubing inlet into
beaker.
C. Rinse tubing directly into volumetric flask (tubing flow may be
reversed in order to more effectively remove particles)
D. QS with appropriate solvent.
ix. Filter wash
A. Using a syringe and appropriate solvent such as acetonitrile or
methanol, flush filter five times into a 50 mL volumetric flask. QS
with solvent
B. Additional dilutions may need to be performed (start with 1:10
dilution)
Screens
Figure A.1: Gastric Emptying Profile Tab in GIS-2 Software
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Appendix B.
MatLAB Code for Duodenal pH and
Titration Simulations
1
2 %%%%pH Time%%%
3
4 c l o s e a l l
5 %%%%Inputs%%%
6
7 % Stomach p r o p e r t i e s
8 Ka_HCl = 10^7; %d i s s o c i a t i o n cons tant o f HCl
9 pKa_HCl = − l og10 (Ka_HCl) ;
10 Vol_HCl = 50E−3; %HCl volume (L)
11 Vol_w = 250E−3; %Water volume (L)
12 C_HCl = 0 . 0 1 ;%HCl ( ac id ) c on c en t r a t i on ( 0 . 0 1 N HCl = 0 .01 M
HCl )
13 Vol_aqs = Vol_w+Vol_HCl ; %%Aqueous volume (L)
14 Sec_Rate_S = 1/60∗10^−3; %Se c r e t i o n f l ow ra t e 2 . 5 mL/min
−−> L/ s )
15 Sec_S_conc = 0 . 0 1 ; %(M)
16 Kw = 2.4825E−14;
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17 Media_replace = 1.5∗10^ −3; %Media rep lacement volume (L)
18
19 %Timing
20 t s t e p = 0 . 5 ; %i n t e r v a l between po i n t s
21 t s t op = 120∗60 ; %l eng th o f s imu l a t i on
22 tspan = ( t s t op / t s t e p )+1; %number o f data po i n t s dur ing
s imu l a t i on
23
24 %Emptying Rate
25 zero_emp = 10E−3; %ra t e o f emptying f o r z e ro o rde r (L/min )
26 Emptying_rate = 15 ; %Emptying r a t e in (min )
27 k = log (2 ) /( Emptying_rate ) ; %emptying r a t e f o r f i r s t o rde r
LEAVE AS POSITIVE
28 % beta = 0 . 8 1 ; %nu f o r Weibul l −−− 0 . 6 f o r median , 1 . 72 f o r
Slow , 0 . 81 f o r mean , 0 . 31 f o r f a s t
29 % nu = 39.42;%gamma f o r Weibul l 23 . 14 f o r median , 100 .13
f o r Slow , 39 .42 f o r mean , 10 .43 f o r f a s t
30 S_vol_stop = 75E−3; %Maintain Volume f o r Stomach (L)
31 beta = 0 . 6 ;
32 nu = 23 . 1 4 ;
33
34 % Duodenum Prop e r t i e s
35 Bulk_conc_D = 10∗10^−3; %i n i t i a l c on c en t r a t i on o f phosphate
in duodenum (M)
36 Sec_Rate_D = 1/60∗10^−3; %Se c r e t i o n f l ow ra t e 1 . 0 mL/min
−−> L/ s )
37 Sec_D_conc = 0 . 0 2 ; %(M)
38 pH_initial_D = 6 . 5 ; %i n i t i a l pH
39 pH_sec_D = 6 . 5 ; %Se c r e t i o n pH
40 Vol_D = 50E−3; %i n i t i a l volume duodenum (L)
41 pka1 = 2 . 1 4 ; %pKa o f H3PO4/H2PO4
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42 pka2 = 6 . 8 ; %pKa o f H2PO4/HPO4
43 ka1 = 10^(−pka1 ) ;
44 ka2 = 10^(−pka2 ) ;
45
46 % Ti t r a t i o n P r op e r t i e s
47 Titrant_Conc = 0 . 1 ; %(M)
48 Titrant_pH = 7 . 0 ;
49 Titrant_pka = 6 . 8 ;
50 Titrant_ka = 10^(−Titrant_pka ) ;
51 Setpoint_pH = 6 . 0 ; %pH to be t i t r a t e d to
52 Threshold_pH = 5 . 5 ; %pH to be t i t r a t e d from
53
54
55
56 Vol_emptying_rate = z e r o s (1 , tspan ) ;
57 Vol_xfer_S = ze r o s (1 , tspan ) ;
58 Vol_s_bulk = z e r o s (1 , tspan ) ;
59 mol_H_xfer = z e r o s (1 , tspan ) ;
60 pH_b_1 = ze r o s (1 , tspan ) ;
61
62 %%%Stomach Tracking%%%
63 %
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
64 %I n i t i a l i z a t i o n o f bulk Conc .
65 H_b_1(1 , 1 ) = (C_HCl∗Vol_HCl/Vol_aqs ) ; %I n i t i a l bulk
c onc en t r a t i on o f H+ (M)
66 pH_b_1(1 , 1 ) = − l og10 (H_b_1(1 , 1 ) ) ;%I n i t i a l bulk PH
67 HA_b_1(1 , 1 ) = 0 ;%I n i t i a l bulk c onc en t r a t i on o f HA
68 A_b_1(1 , 1 ) = 0 ;%I n i t i a l bulk c onc en t r a t i on o f A−
69 HCl_b_1(1 , 1 ) = 0 ;%I n i t i a l bulk c onc en t r a t i on o f HCl
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70
71 Vol_s_bulk ( 1 , 1 ) = Vol_aqs ; %V0 f o r stomach (L)
72
73 f o r t index = 2 : tspan
74
75 t = ( t index − 1) ∗ t s t e p ;
76
77 %Emptying Regime S e l e c t i o n
78 i f Vol_s_bulk ( 1 , ( t index −1) ) > S_vol_stop
79 % Vol_emptying_rate (1 , t i ndex ) = zero_emp /60 ; %
Zero orde r emptying r a t e (L/ s e c )
80 Vol_emptying_rate (1 , t index ) = (Vol_aqs∗k∗exp(−k ∗( t
/60) ) ) /60 ; %f i r s t o rde r emptying (L/ s e c )
81 % Vol_emptying_rate (1 , t i ndex ) = ( ( Vol_aqs∗ beta /( t
/60) ∗exp ( − ( ( ( t /60) /nu )^beta ) ) ∗ ( ( ( t /60)^beta ) /nu ) ) ) /60 ; %
Weibul l emptying r a t e (L/ s e c )
82 e l s e
83 Vol_emptying_rate (1 , t index ) = 0 ; %s top s net
emptying o f Stomach at stop volume , s im i l a r to
mainta in f un c t i on
84
85 end
86
87 %Xfer to Duodenum
88 Vol_xfer_S (1 , t index ) = ( Vol_emptying_rate (1 , t index ) ∗
t s t e p )+Sec_Rate_S∗ t s t e p ; % Volume l e a v i n g Stomach at
t (L)
89 mol_H_xfer (1 , t i ndex ) = ( Vol_xfer_S (1 , t index ) ) ∗H_b_1(1 ,
t index −1) ; %mol o f H l e a v i n g Stomach at t (mol )
90
91 %Updates in Stomach
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92 Vol_s_bulk (1 , t i ndex ) = Vol_s_bulk ( 1 , ( t index −1) ) −
Vol_xfer_S (1 , t index ) + Sec_Rate_S∗ t s t e p ; %Current
vo l o f Stomach (mL)
93 H_b_1(1 , t index ) = (H_b_1(1 , t index −1)∗Vol_s_bulk ( 1 , (
t index −1) ) + ( ( Sec_Rate_S∗ t s t e p ) ∗Sec_S_conc ) −
mol_H_xfer (1 , t i ndex ) ) . / Vol_s_bulk ( 1 , ( t index ) ) ; %
cu r r en t proton conc en t r a t i on (M)
94 pH_b_1(1 , t index )= − l og10 (H_b_1(1 , t index ) ) ;%cu r r en t pH
in stomach
95
96 % %Media Replacement Check
97 % i f ismember ( t
, [ 1 20 , 3 00 , 6 00 , 9 00 , 1 800 , 2 700 , 3600 , 4500 , 5 400 ] ) == 1
98 % H_b_1(1 , t index ) = (H_b_1(1 , t index ) ∗Vol_s_bulk
(1 , t i ndex ) − H_b_1(1 , t index ) ∗Media_replace + Sec_S_conc∗
Media_replace ) /Vol_s_bulk (1 , t i ndex ) ;
99 % end
100 end
101
102
103 %%%%%%%%%%%%%%%
104 %%%Duodenum Tracking%%%
105 %%%%%%%%%%%%%%%
106
107 %%%%%%%%%%%
108 %%%I n i t i a l i z a t i o n%%%
109 %%%%%%%%%%%
110 H2B_D = ze r o s (1 , tspan ) ;
111 HB_D = ze r o s (1 , tspan ) ;
112 H_D = ze r o s (1 , tspan ) ;
113 x_d = ze r o s (1 , tspan ) ;
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114 pH_D = ze r o s (1 , tspan ) ;
115 Vol_Xfer_D = ze r o s (1 , tspan ) ;
116 H2B_bb_D = ze r o s (1 , tspan ) ;
117 HB_bb_D = ze r o s (1 , tspan ) ;
118 HB_ab_D = ze r o s (1 , tspan ) ;
119 H2B_ab_D = ze r o s (1 , tspan ) ;
120 H3B_bb_D = ze r o s (1 , tspan ) ;
121 H3B_ab_D = ze r o s (1 , tspan ) ;
122 Total_B = ze r o s (1 , tspan ) ;
123 H2B_bb_D_2 = ze r o s (1 , tspan ) ;
124 HB_bb_D_2 = ze r o s (1 , tspan ) ;
125 H_D_preT = ze r o s (1 , tspan ) ;
126 H2B_D_preT = ze r o s (1 , tspan ) ;
127 Titrant_H = ze r o s (1 , tspan ) ;
128 Titrant_P = ze r o s (1 , tspan ) ;
129 Vol_Titrant = z e r o s (1 , tspan ) ;
130 Total_Vol_Titrant = z e r o s (1 , tspan ) ;
131
132 %%%
133 pH_D(1 , 1 ) = pH_initial_D ; %I n i t i a l pH in D
134 H_D(1 , 1 ) = (10^−pH_initial_D ) ; %Proton conc en t r a t i on (M)
135 HB_D(1 , 1 ) = Bulk_conc_D∗ka2 /(H_D(1 , 1 )+ka2 ) ; %Concentrat ion
o f HPO4 (2−) M
136 H2B_D(1 , 1 ) = Bulk_conc_D − HB_D(1 , 1 ) ; %conc en t r a t i on o f
H2PO4(−) M
137 H3B_D(1 , 1 ) = 0 ; % almost no chance there ' s any H3PO4 ever ,
but . . .
138 Vol_Xfer_D (1 , 1 ) =0; %no f l u i d t r a n s f e r at t=0
139 Total_B (1 , 1 ) = HB_D(1 , 1 ) + H2B_D(1 , 1 ) + H3B_D(1 , 1 ) ; %t o t a l
PO4 conc en t r a t i on in D
140
131
141 %%%s e c r e t i o n c on c en t r a t i o n s
142 H_D_Sec = (10^−pH_sec_D) ; %(M)
143 HB_D_Sec = Sec_D_conc∗ka2 /(H_D_Sec+ka2 ) ; %Concentrat ion o f
HPO4 (2−) M
144 H2B_D_Sec = Sec_D_conc − HB_D_Sec ; %conc en t r a t i on o f H2PO4
(−) M
145
146 %Tit rant c a l c u l a t i o n s
147
148 mEq_Titrant = Titrant_Conc∗Titrant_ka /(10^−Titrant_pH+
Titrant_ka ) − Titrant_Conc∗Titrant_ka /(10^−Setpoint_pH+
Titrant_ka ) ; %mEq that can be absorbed by 1 mL o f b u f f e r
t i t r a n t to e q u i l i b r a t e at Se tpo in t
149 d i sp (mEq_Titrant ) ;
150
151 f o r t index = 2 : tspan
152
153 t = ( t index − 1) ∗ t s t e p ;
154
155 % i f pH_D(1 , ( t index −1) ) > 3 . 5
156 W=@(Hdel lp ) −10^−pH_D(1 , t index −1)−10^−pH_b_1(1 ,
t index −1) . ∗ Vol_xfer_S (1 , t index −1)/Vol_D+10^−pH_D
(1 , t index −1) . ∗ Vol_Xfer_D (1 , t index −1)/Vol_D−10^−
pH_sec_D . ∗ Sec_Rate_D∗ t s t e p /Vol_D+Hdel lp+(Hdel lp ∗
HB_D(1 , t index −1) /( Hdel lp+ka2 ) ) −((Kw/Hdel lp )+(ka2
∗H2B_D(1 , t index −1) /( Hdel lp+ka2 ) ) )+Kw/(10^−pH_D
(1 , t index −1)−10^−pH_D(1 , t index −1) . ∗ Vol_Xfer_D (1 ,
t index −1)∗ t s t e p /Vol_D+10^−pH_b_1(1 , t index −1) . ∗
Vol_xfer_S (1 , t index −1)/Vol_D+10^−pH_sec_D . ∗
Sec_Rate_D∗ t s t e p /Vol_D) ;
157 % e l s e
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158 % W=@(Hdel lp ) −10^−pH_D(1 , t index −1)−10^−pH_b_1(1 ,
t index −1) . ∗ Vol_xfer_S (1 , t index −1)/Vol_D+10^−pH_D(1 ,
t index −1) . ∗ Vol_Xfer_D (1 , t index −1)/Vol_D−10^−pH_sec_D . ∗
Sec_Rate_D∗ t s t e p /Vol_D+Hdel lp+(Hdel lp ∗H2B_D(1 , t index −1)
/( Hdel lp+ka1 ) ) −((Kw/Hdel lp )+(ka1∗H3B_D(1 , t index −1) /(
Hdel lp+ka1 ) ) )+Kw/(10^−pH_D(1 , t index −1)−10^−pH_D(1 , t index
−1) . ∗ Vol_Xfer_D (1 , t index −1)∗ t s t e p /Vol_D+10^−pH_b_1(1 ,
t index −1) . ∗ Vol_xfer_S (1 , t index −1)/Vol_D+10^−pH_sec_D . ∗
Sec_Rate_D∗ t s t e p /Vol_D) ;
159 % end
160
161 H_D(1 , t index )=f z e r o (W,[10^ −0 10^ −14]) ;
162 pH_D(1 , t index ) = − l og10 (H_D(1 , t index ) ) ;
163
164 % i f pH_D(1 , t index ) > 3 . 5
165 H2B_bb_D(1 , t index ) = H_D(1 , t index ) . ∗HB_D(1 , t index
−1) . / (H_D(1 , t index )+ka2 ) ;%Acid bu f f e r de r i v ed
from base
166 HB_bb_D(1 , t index ) = ka2∗H2B_bb_D(1 , t index ) . /H_D(1 ,
t index ) ;%Base bu f f e r de r i v ed from base
167 HB_ab_D(1 , t index ) = ka2∗H2B_D(1 , t index −1) . / (H_D(1 ,
t index )+ka2 ) ;%Base bu f f e r de r i v ed from ac id
168 H2B_ab_D(1 , t index ) = H_D(1 , t index ) . ∗HB_ab_D(1 ,
t index ) /ka2 ;%Acid bu f f e r de r i v ed from ac id
169 H3B_ab_D(1 , t index ) = 0 ;
170 H3B_bb_D(1 , t index ) = 0 ;
171
172 H2B_D(1 , t index ) = H2B_ab_D(1 , t index ) + H2B_bb_D(1 ,
t index ) ;
173 HB_D(1 , t index ) = HB_ab_D(1 , t index ) + HB_bb_D(1 ,
t index ) ;
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174 H3B_D(1 , t index ) = H3B_ab_D(1 , t index ) + H3B_bb_D(1 ,
t index ) ;
175 % e l s e
176 % H2B_bb_D_2(1 , t index ) = H_D(1 , t index ) . ∗HB_D(1 ,
t index −1) . / (H_D(1 , t index )+ka2 ) ;%Acid bu f f e r de r i v ed from
base
177 % HB_bb_D_2(1 , t index ) = ka2∗H2B_bb_D(1 , t index ) . /H_D
(1 , t index ) ;%Base bu f f e r de r i v ed from base
178 % H3B_bb_D(1 , t index ) = H_D(1 , t index ) . ∗H2B_D(1 ,
t index −1) . / (H_D(1 , t index )+ka1 ) ;%Acid bu f f e r de r i v ed from
base
179 % H2B_bb_D(1 , t index ) = ka1∗H3B_bb_D(1 , t index ) . /H_D
(1 , t index ) ;%Base bu f f e r de r i v ed from base
180 % H2B_ab_D(1 , t index ) = ka1∗H3B_D(1 , t index −1) . / (H_D
(1 , t index )+ka1 ) ;%Base bu f f e r de r i v ed from ac id
181 % H3B_ab_D(1 , t index ) = H_D(1 , t index ) . ∗H2B_ab_D(1 ,
t index ) /ka1;%Acid bu f f e r de r i v ed from ac id
182 %
183 % HB_D(1 , t index ) = HB_bb_D_2(1 , t index ) ;
184 % H2B_D(1 , t index ) = H2B_bb_D_2(1 , t index ) + H2B_ab_D
(1 , t index ) + H2B_bb_D(1 , t index ) ;
185 % H3B_D(1 , t index ) = H3B_ab_D(1 , t index ) + H3B_bb_D
(1 , t index ) ;
186 %
187 % end
188
189
190
191 %update c on c en t r a t i o n s f o r input s
192 H2B_D(1 , t index ) = (H2B_D(1 , t index ) ∗Vol_D +
Sec_Rate_D∗ t s t e p ∗H2B_D_Sec) /Vol_D ; %Current +
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Input from Se c r e t i o n
193 HB_D(1 , t index ) = (HB_D(1 , t index ) ∗Vol_D + Sec_Rate_D
∗ t s t e p ∗HB_D_Sec) /Vol_D ; %Current + input from
Se c r e t i o n
194 H_D(1 , t index ) = H_D(1 , t index )+(mol_H_xfer (1 , t i ndex )
+(Sec_Rate_D∗ t s t e p ∗H_D_Sec) /Vol_D) ; %Current +
input from Stomach + Input from Se c r e t i o n
195
196 %Update f o r Exit
197 Vol_Xfer_D (1 , t index ) = Vol_xfer_S (1 , t index ) +
Sec_Rate_D∗ t s t e p ; %(mL) l e a v i n g Duodenum to
maint ian volume
198 H3B_D(1 , t index ) = (H3B_D(1 , t index ) ∗Vol_D − (
Vol_Xfer_D (1 , t index ) ) ∗H3B_D(1 , t index ) ) /Vol_D ; %
Current Mol − Mol l e a v i n g over cu r r en t vo l
199 H2B_D(1 , t index ) = (H2B_D(1 , t index ) ∗Vol_D − (
Vol_Xfer_D (1 , t index ) ) ∗H2B_D(1 , t index ) ) /Vol_D ;
200 HB_D(1 , t index ) = (HB_D(1 , t index ) ∗Vol_D − (
Vol_Xfer_D (1 , t index ) ) ∗HB_D(1 , t index ) ) /Vol_D ;
201 H_D(1 , t index ) = (H_D(1 , t index ) ∗Vol_D − (Vol_Xfer_D
(1 , t index ) ) ∗H_D(1 , t index ) ) /Vol_D ;
202 Total_B (1 , t index ) = HB_D(1 , t index ) + H2B_D(1 , t index
)+H3B_D(1 , t index ) ; %Update cu r r en t t o t a l PO4
conc en t r a t i on in D
203
204 % %Media Replacement Check
205 % i f ismember ( t
, [ 1 20 , 3 00 , 6 00 , 9 00 , 1 800 , 2 700 , 3600 , 4500 , 5 400 ] ) == 1
206 % H2B_D(1 , t index ) = (H2B_D(1 , t index ) ∗Vol_D −
H2B_D(1 , t index ) ∗Media_replace + H2B_D_Sec∗Media_replace )
/Vol_D ;
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207 % HB_D(1 , t index ) = (HB_D(1 , t index ) ∗Vol_D − HB_D
(1 , t index ) ∗Media_replace + HB_D_Sec∗Media_replace ) /Vol_D
;
208 % H_D(1 , t index ) = (H_D(1 , t index ) ∗Vol_D − H_D(1 ,
t index ) ∗Media_replace + H_D_Sec∗Media_replace ) /Vol_D ;
209 % end
210
211 %Ti t r a t i o n Check
212 i f pH_D(1 , t index ) < Threshold_pH
213 H_D_preT(1 , t index ) = H_D(1 , t index ) ;
214 H2B_D_preT(1 , t index ) = H2B_D(1 , t index ) ;
215 H_D(1 , t index ) = 10^−Setpoint_pH ;
216
217 %re− e q u i l i b r a t i n g bu f f e r f o r new pH
218 %( assumes NaOH consumes a l l H+ to move pH from
Threshold −−> Setpo in t )
219 HB_D(1 , t index ) = Total_B (1 , t index ) ∗ka2 /(H_D(1 ,
t index )+ka2 ) ; %Concentrat ion o f HPO4 (2−) M
220 H2B_D(1 , t index ) = Total_B (1 , t index ) − HB_D(1 ,
t index ) ; %conc en t r a t i on o f H2PO4(−) M
221
222 %Ca l cu l a t e Volume based on [H+] in s o l u t i o n and
[H+}
223 %d i s s o c i a t e d from H2B −>HB
224 Titrant_H (1 , t index ) = H_D_preT(1 , t index )−H_D(1 ,
t index ) ; %mEq r equ i r e d ( e f f e c t i v e l y , though
i t ' s not c o r r e c t e d f o r volume u n t i l below
225 Titrant_P (1 , t index ) = H2B_D_preT(1 , t index )−
H2B_D(1 , t index ) ; %mEq r equ i r e d ( e f f e c t i v e l y )
226 Vol_Titrant (1 , t index ) = ( Titrant_H (1 , t index )+
Titrant_P (1 , t index ) ) ∗Vol_D/mEq_Titrant ; %(L
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)
227
228 %Reca l cu l a t e c on c en t r a t i o n s to mainta in volume
ba lance
229 Total_B (1 , t index ) = ((1−Vol_Titrant (1 , t index ) )
∗(Total_B (1 , t index ) ∗Vol_D + Titrant_Conc∗
Vol_Titrant (1 , t index ) ) ) /Vol_D ;
230 HB_D(1 , t index ) = Total_B (1 , t index ) ∗ka2 /(H_D(1 ,
t index )+ka2 ) ; %Concentrat ion o f HPO4 (2−) M
231 H2B_D(1 , t index ) = Total_B (1 , t index ) − HB_D(1 ,
t index ) ; %conc en t r a t i on o f H2PO4(−) M
232 H_D(1 , t index ) = 10^−Setpoint_pH ;
233
234 pH_D(1 , t index ) = Setpoint_pH ;
235 end
236 Total_Vol_Titrant (1 , t i ndex ) = Total_Vol_Titrant ( 1 , (
t index −1) ) + Vol_Titrant (1 , t i ndex ) ;
237 end
238
239 x = l i n s p a c e (0 , l eng th (pH_b_1) /120 , l eng th (pH_b_1) ) ;
240 f i g u r e
241 p l o t ( x , pH_b_1, x ,pH_D)
242 t i t l e ( 'Drug− l e s s pH p r o f i l e f o r GIS−2 ' )
243 l egend ( ' Stomach ' , 'Duodenum ' , ' Locat ion ' , ' b e s t ' )
244 x l a b e l ( 'Time (min ) ' )
245 y l a b e l ( 'pH ' )
246
247 f i g u r e
248 p l o t ( x , Total_B )
249 t i t l e ( 'Drug− l e s s pH p r o f i l e f o r GIS−2 ' )
250 l egend ( ' Phosphate ' , ' Locat ion ' , ' b e s t ' )
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251 x l a b e l ( 'Time (min ) ' )
252 y l a b e l ( ' [ Total PO4 ] ' )
253 %
254 % f i g u r e
255 % plo t (x ,H3B_D, x ,H2B_D, x ,HB_D)
256 % t i t l e ( ' Drug− l e s s pH p r o f i l e f o r GIS−2 ')
257 % legend ( 'H3PO4' , 'H2PO4' , 'HPO4' , ' Locat ion ' , ' best ' )
258 % x l ab e l ( ' Time (min ) ' )
259 % y l ab e l ( ' [ PO4 ] Spec i e s ' )
260
261 f i g u r e
262 p l o t ( x , Total_Vol_Titrant ∗10^3)
263 t i t l e ( 'Drug− l e s s pH p r o f i l e f o r GIS−2 ' )
264 l egend ( ' T i t ran t ' , ' Locat ion ' , ' b e s t ' )
265 x l a b e l ( 'Time (min ) ' )
266 y l a b e l ( ' vo l (mL) Ti t rant ' )
267
268 f i g u r e
269 p l o t ( x , Titrant_H ∗10^3 ,x , Titrant_P ∗10^3)
270
271 t i t l e ( 'Drug− l e s s pH p r o f i l e f o r GIS−2 ' )
272 l egend ( 'H ' , 'P ' , ' Locat ion ' , ' b e s t ' )
273 x l a b e l ( 'Time (min ) ' )
274 y l a b e l ( ' vo l (mL) Ti t rant ' )
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Appendix C.
Example User-Defined Gastric
Emptying Method for Testing
User-Defined Profile Function
Time (min) Emptying Profile
0-0.5 Held at 200
0.5-10 min 1st Order Emptying, 30 min half emptying time
10 - 15 min 7 mL/min
15 - 25 min 1st Order Emptying, 10 min half emptying time
25 - 35 min 2 mL/min
Table C.1: Summary of Emptying Profile Cycles for GIS-2 User Defined Test for Pump
Validation
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Appendix D.
Tables for Formulations
140
Table D.1: Plackett-Burman Table for Formulations141
Table D.2: Formulation descriptions for each formulation. For excipients, masses listed are in mg.
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